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1. Introduction 
Adenoviruses (AdV) have been well delineated and made into suitable vectors for gene 
transfer by their somewhat benign nature, broad tissue tropism, and the relative ease of 
manipulation of their genome. These viruses readily transduce both quiescent and dividing 
cells, are adaptable for large scale production and have certified cell lines that have been 
developed for purification. Nevertheless, these vectors are not recommended for all 
purposes.  Currently, adenoviral vectors are more widely evaluated in applications where a 
short-term transgene expression is sought after (i.e., cancer and vaccines) (Jolly et al., 2008; 
Sharma et al., 2009b). 
Rowe and colleagues in 1953 were the first to isolate AdV from adenoidal tissue and to 
describe the spontaneous degeneration of primary cell lines from whence they were derived 
(Rowe WP et al., 1953). A similar virus was isolated from an epidemic of respiratory illness 
in U.S. military recruits in 1954 (Hilleman MR & Werner JH, 1954). In 1956, the viruses were 
named adenoviruses after the tissue from which they were isolated (Enders et al., 1956). 
Their anti-tumor potential was explored in the clinical treatment of cervical carcinoma 
following AdV inoculation not long after 1956 (Huebner et al., 1956).  Despite this initial use, 
it took several years following the advent of recombinant technology before the therapeutic 
potential of AdV was truly realized.  Since then, adenoviral vectors have received much 
attention as gene transfer agents and currently are being tested in a wide variety of gene 
therapy applications. 
There are more than 120 AdV that infect a wide host range including mammalian, avian, 
and reptile species.  AdV are divided into four genera: Atadenovirus, Aviadenovirus, 
Mastadenovirus, and Siadenovirus. Mastadenovirus serotypes which infect humans are 
placed in groups (A-F) or subgenera.  Initial parameters for grouping were based on 
patterns of hemagglutination from various animal species; now the grouping is based on 
DNA homology.  Some of these genera are being engineered for use as AdV vectors. 
The Adenoviridae family is characterized by a linear, double-stranded DNA genome that is 
encapsulated in an icosohedral shell of protein that measures 70 to 90 nm in diameter. 
Virions of AdV are comprised of 13% DNA and 87% protein (Rux & Burnett, 2004; San & 
Burnett, 2003).  Their genome is approximately 35-38 kilobases in size.   The majority of the 
viral capsid encompasses three proteins: fiber, penton base and hexon.  Fiber and penton 
base proteins are necessary for receptor binding and cell internalization, whereas hexon 
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proteins form most of the viral capsid.  These three proteins are also crucial targets of virus 
neutralizing antibodies. 
AdV infections are common in humans and have relatively benign sequelae. Primarily, they 
are the etiologic agents that cause upper and lower respiratory infections. However, they do 
infect other tissues such as the eyes, gastrointestinal and urinary tracts, brain, heart, kidney, 
and liver where they pose minor health risks.  Individuals with a normal immune system 
have self-limiting infections without notable clinical sequelae. Yet immunocompromised 
individuals may develop conditions more frequently associated with uncommon variants 
(i.e., group B, serotype 35). During infection, adenoviral DNA is not usually integrated into 
host cell chromosomes thereby minimizing concerns regarding insertional mutagenesis or 
potential germ line risks.  The clinical mildness of a natural AdV infection is probably 
attributed to their immunogenicity which has made these viruses popular as gene transfer 
vectors.   In spite of this positive side of their immunogenicity, these viruses without 
considerable modifications may not be useful for applications that necessitate long-term 
expression since they do not incorporate into the host genome. 
1.1 Advantages of AdV vectors 
There are several factors that contribute to the advantages of AdV-based vectors.  The 
molecular mechanisms underlying the AdV genome and its life cycle have been extensively 
studied which has facilitated molecular manipulations of the viral genome in plasmid 
form.  Only the packaging signal and the inverted terminal repeat (ITR) (approximately 
300bp) are essential to package nearly 105% of the total AdV genome.  This facilitates a 
decrease in the occurrence of replication-competent recombinants while also permitting 
introduction of a large transgene cassette (up to approx. 35kb) into the AdV 
virion.  Additional benefits include relatively simple and reliable manufacturing methods, 
high levels of expression in various replicating and non-replicating tissues even at low 
temperatures, delineation of its toxicity profile, minimized risk of genomic insertional 
mutagenesis due to its episomal persistence in the nucleus, and extensive knowledge of the 
effects pertaining to vector genome uptake following a particular route of administration.  
Also, AdV vectors have demonstrated the ability to prime and boost T- and B-cell responses 
(Pinto et al., 2003; Vemula & Mittal, 2010). Most importantly, safety has been demonstrated 
in the therapeutic application of AdV vectors in a number of clinical trials (Sharma et al., 
2009b). 
AdV vectors can be generated to express multiple proteins from various expression cassettes 
located within the genome of the AdV. Vaccine formulations that exploit the advantages of 
these AdV vectors increase the potency and reduce the prospective costs.  Also the use of 
multi-gene expression technology permits flexibility in vaccine design regarding rapid 
antigen swapping after AdV vector development. A prerequisite for such an AdV vector is 
that it must adequately express multiple antigens (Jolly et al., 2008). Finally, while some may 
view the transient nature of AdV vectors to be a disadvantage, it does have beneficial 
medical applications. AdV vectors have demonstrated therapeutic potential in treating 
various forms of cancer, infectious disease, and tissue remodeling. 
1.2 Disadvantages of AdV vectors 
Transient expression of the transgene by AdV vectors can be a disadvantage for gene 
therapy applications where continous expression of the trangene is necessary for a desired 
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therapeutic effect. Due to the promiscuous nature of AdV biodistribution following systemic 
administration, targeting of the AdV vector to only a specific cell type is a considerable 
challenge. 
AdV vectors at a very high dose could lead to significant toxicity. Expression of  
viral proteins by the AdV vector and activation of innate immunity are partially 
responsible for this in vivo toxicity. The deadly potential of AdV in vivo toxicity was 
highlighted after the intravascular delivery of an AdV to a patient enrolled in a clinical 
trial in 1999. A large dose of vector was administered into the hepatic artery of the patient 
recruited in a partial ornithine transcarbamylase (OTC) deficiency clinical trial.  This large 
dose resulted in  liver dysfunction and death due to multiple organ failure (Raper et al., 
2003). The investigators concluded that the toxicity was due to the ‘extremely high dose’ 
(3.8 x 1013 virus particles) of AdV causing a saturation of the available AdV receptors on 
hepatocytes and the subsequent spread of the vector to other organs. The patient’s death 
was thought to be due to strong activation of an innate immune response. This 
unfortunate event has led to new guidelines for the validation of new technologies.   
AdV are a common human pathogen, especially human adenovirus 5 (HAdV5); therefore, in 
vivo delivery of AdV may be hampered due to pre-existing vector immunity in the majority 
of human population.  Although low levels of vector immunity can be quelled by increasing 
the dose of administered AdV vector  without increasing toxic side effects (Pratt et al., 2010), 
the issue of pre-existing vector immunity is a cause for concern.  Challenges also exist in 
correlating the protective outcomes of the quality of T cell responses over the quantity of T 
cells that are stimulated by different immunization protocols and vector strategies.  Priming 
with some AdV vectors stimulates transgene-specific immune responses that have a low 
correlation with type I interferon (IFN) production; the reduced levels are associated with 
reduced transgene expression. Reduced IFN also hampers quality T cell responses and B cell 
differentiation into effector plasma cells. However, too much type I IFN results in clearance 
by innate effector systems and poor transgene expression.  Thus, type I IFN responses must 
be rigidly controlled to attain therapeutic efficacy (Draper & Heeney, 2010). 
2. AdV induced innate immune response 
The AdV vector-mediated acute toxicity subsequent to intravascular inoculation is known to 
be a direct result of potent activation of the innate immune system - a desirable outcome for 
the purpose of vaccine development or cancer immunotherapy (Muruve, 2004). The 
activated immune system in these scenarios also results in the induction of a stronger 
immune response against the desired antigen or cancer cells. However, this strong immune 
reaction remains an obstacle for AdV-mediated gene therapy since the danger of severe 
toxicity prevents administration of the dose necessary to achieve the desirable therapeutic 
effect. The immune system activation follows a dose-dependent pattern and is independent 
of viral gene expression. Immune system activation is manifested as severe liver 
inflammation, thrombocytopenia, and systemic flu-like symptoms such as fever and 
myalgias (Raper et al., 2002). The severe inflammatory response is also associated with poor 
target cell tranduction and loss of viral genome and transgene expression within two to 
three weeks post administration (Yang et al., 1994). 
The initial host response to AdV vectors occurs within minutes after systemic 
administration and may last from several hours to days. It is characterized by elevated 
serum levels of proinflammatory cytokines such as tumor necrosis factor- ǂ (TNF- ǂ), IL-
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6, IL-1ǃ, IFN-Ǆ, and chemokines such as macrophage inhibitory protein (MIP)-2, IFN-Ǆ 
inducible protein 10 (IP-10), RANTES, MIP-1ǂ, MIP-1ǃ and monocyte chemoattaractant 
protein 1 ((MCP-1) (Muruve et al., 2004). Induction of inflammatory response to viral 
pathogens proceeds through opsonization, uptake of opsonized viral particles, antigen 
processing and presentation, and, finally, the release of inflammatory cytokines. Likewise, 
high doses of systemically administered AdV vectors result in activation of splenic 
dendritic cells (DCs) and macrophages inducing the production of inflammatory 
cytokines such as IL-6, IL-12 and TNF-ǂ. Depletion of tissue macrophages and DCs 
prevents the production of the aforementioned cytokines, indicating a central role of these 
innate effectors in the acute inflammatory response (Kuzmin et al., 1997; Lieber et al., 
1997; Zhang et al., 2001). Recently, an in vitro study using co-culture of epithelial cells and 
macrophages demonstrated the dependence of AdV-induced inflammatory response on 
the activation of macrophages through interactions with epithelial cells where the 
activation was mediated by NF-κB. AdV infection of the co-culture resulted in 
cytotoxicity, expression of inflammatory cytokines and chemokines, NOS and ROS 
generation and activation of inflammatory transcription factors (Lee et al., 2010).  
However, the nature of macrophage and epithelial cell interaction and their implications 
during AdV infection in vivo remain to be elucidated.  
Neutrophils also seem to play an important role in AdV-induced acute inflammation. The 
chemokines, MCP-1, RANTES and MIP-1ǃ, upregulate the neutrophil chemoattaractant 
chemokine MIP-2 which then recruits neutrophils to the liver. Recruitment of neutrophils 
and rapid induction of C-C and C-X-C chemokines correlates with acute liver injury and 
histopathological changes (Muruve et al., 1999). Moreover, AdV vectors are shown to 
activate endothelium in post-sinusoidal venules and promote P and E selectin-mediated 
rolling. This is followed by adhesion mediated through interactions between ǂ4-integrin 
on the neutrophil surface and vascular cell adhesion molecule-1 (VCAM-1) on endothelial 
cells (Li et al., 2002). Blocking of either leukocyte rolling and adhesion or neutrophil 
depletion results in lower expression of the proinflammatory gene expression implying a 
central role of neutrophils in AdV-induced liver inflammation (Liu et al., 2003b). The 
neutrophils are recruited to the liver where they take up AdV particles in a complement 
receptor 1 (CR1)- and Fc receptor-dependent manner sequestering the AdV particles away 
from target cells (Cotter et al., 2005). How the neutrophil sequestration of AdV particles 
affects the vector-induced innate immune response calls for further exploration. Although 
other types of leukocytes such as monocytes and macrophages are also recruited to the 
liver, neutrophils constitute more than 70% of the total leukocytes in the liver following 
systemic AdV administration. 
Natural killer (NK) cells are another cell type activated and populated to the liver following 
AdV infection and are directly associated with liver injury. Type 1 IFNs, produced in 
response to viral infection, promote activation of NK cells which mediate clearance of AdV 
genome and lowers transgene expression. Pre-treatment with anti-NK cells antibodies 
enhances AdV genome persistence, prolongs transgene expression and dampens the innate 
immune-mediated liver injury (Liu et al., 2003a; Zhu et al., 2007). A very interesting strategy 
to mitigate the impact of AdV-induced innate immune response would be to transiently 
remove the effector cells of the innate immune system, such as neutrophil and NK cells. 
Alternatively, in the light of evidence of IFN-Ǆ-mediated NK cell activation, transient 
suppression of type 1 IFN response prior to AdV administration might also be beneficial 
(Zhu et al., 2007). 
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Several studies in the recent past have focused on delineating the molecular mechanisms 
governing AdV-mediated activation of the innate immune system. This system, being the 
first line of defense against invading pathogens, has evolved a highly conserved repertoire 
of ‘pattern recognition receptors (PRRs)’ which specifically identify ‘pathogen-associated 
molecular patterns (PAMPs)’ (Kumar et al., 2009). A variety of PRRs, including Toll-like 
receptors (TLRs), RIG-1-like receptors (RLRs) and Nod-like receptors (NLRs), are employed 
for the recognition of all types of pathogens ranging from bacteria, fungi, viruses and 
protozoa.  
2.1 Role of TLR signaling in AdV-induced innate immune response 
Depending on the cell type, the sensing of AdV by innate immune response is mediated by 
both TLR-dependent and independent pathways and appears to be very complex 
(Appledorn et al., 2008b; Cerullo et al., 2007; Nociari et al., 2007; Zhu et al., 2007).  Among 
the members of the TLR family, four are known to recognize viral nucleic acids: TLR3 
(dsRNA), TLR7, TLR8 (ssRNA) and TLR9 (dsDNA). The myeloid differentiation primary 
response gene 88 (MyD88), a TLR Adaptor protein for downstream activation of  signaling 
cascades such as MAPK and NF-κB pathways, is necessary to initiate an AdV-induced 
proinflammatory cytokine and chemokine response (Hartman et al., 2007a; Hartman et al., 
2007b). TLR9 is spatially and temporally co-localized with AdV as it is expressed in 
endosomes and is specifically upregulated during AdV infection. As a result, it effectively 
recognizes unmethylated CpG motifs in dsDNA released after proteolytic degradation of 
AdV particles within endosomes and initiates a signaling cascade through MyD88 in 
plasmacytoid DCs (pDCs).  This culminates with their maturation and the production of 
high levels of type 1 IFNs as witnessed during AdV infection. The type 1 IFN production in 
pDCs is TLR9/MyD88-dependent, as opposed to non-pDCs which recognize AdV DNA 
through a cytosolic sensor different from TLR9.  Significant amounts of type 1 IFNs are 
produced with an AdV infection. In addition to the activation of NK cells, the type 1 IFNs 
play a crucial role in the AdV-mediated activation of innate immune response by enhancing 
production of proinflammatory cytokines IL-6 and IL-12 (Zhu et al., 2007). TLR2 also plays a 
crucial role regulating AdV-induced innate immune response by mediating the rapid 
activation of MAPK and NF-kB pathways which are linked to induction of inflammatory 
cytokine and chemokine gene expression. Specifically, TLR2 is required for sustained late 
phase induction of these pathways; initial activation is TLR2 independent (Appledorn et al., 
2008b; Tibbles et al., 2002).  
The induction of chemokines MCP-1 and RANTES depends solely on TLR-9 within one 
hour post-infection (hpi), but relies on both TLR2 and TLR9 at eight hpi. Collectively, 
TLR2 and TLR9 play crucial roles through the differential induction of cytokines and 
chemokines. However, the induction of chemokines independent of both TLR2 and TLR9, 
was discovered to be MyD88-dependent at beth early and late time points suggesting the 
involvement of different MyD88- dependent sensors in the full spectrum induction of 
innate immune response (Appledorn et al., 2008b). 
As noted above, AdV infection of non-pDCs such as conventional DCs (cDCs), macrophages 
and fibroblasts stimulates production of significant amounts of type 1 IFNs, 
proinflammatory cytokines and chemokines through phosphorylation of interferon 
regulatory factor (IRF)-3. The activation of IRF-3 occurs as a result of the recognition of AdV 
DNA by a yet unidentified cytosolic DNA sensor which promotes phosphorylation of IRF-3. 
The phosphorylation initiates IRF-3 dimerization and translocation to the nucleus where it 
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causes transcriptional activation of several IRF-3 responsive inflammatory cytokine and 
chemokine genes (Hiscott, 2007; Nociari et al., 2007). However, AdV vectors can also induce 
IRF-3 phosphorylation directly through the capsid-cell membrane interactions prior to the 
endosomal escape of viral DNA, thereby providing an additional IRF-3 activation signal for 
stronger IFN and inflammatory response (Nociari et al., 2009).  Evidently, AdV infection 
induces type 1 IFN response through multiple pathways and, therefore, causes a very strong 
activation of IFN responsive genes which might explain the powerful induction of innate 
immune response following AdV infection. 
The NALP3 protein, a type of Nod-like receptor, plays an important role in cytosolic sensing 
of AdV DNA and the subsequent induction of proinflammatory IL-1ǃ response. However, 
NALP3 is a general sensor for any kind of dsDNA including viral, bacterial, or even host 
(mammalian DNA) (Martinon et al., 2009). AdV DNA was shown in vitro to activate NALP3 
signaling events through apoptosis-associated speck-like protein containing caspase 
recruitment domain (ASC), the adaptor protein for NALP3, resulting in the recruitment of 
the inflammatory caspase-1 into the molecular complex called the inflammasome which 
activates caspase-1. The activated caspase-1 initiates the proteolytic cleavage of pro-IL-1ǃ 
into an active and secreted form of IL-1ǃ. A similar response was detected upon infection 
with first generation AdV vectors, helper-dependent (HD) AdV vectors, and by transfecting 
cells with AdV DNA implying that the nature of DNA did not affect inflammasome 
activation.  However, empty capsids failed to elicit a similar response suggesting that mere 
internalization of the capsid proteins was not enough for the inflammatory response. 
Furthermore, NALP-, ASC- and caspase-1-deficient mice systemically injected with AdV 
vectors developed only a blunted inflammatory response in the liver and showed a 
remarkable reduction in the expression of NF-kB regulated pro-inflammatory genes 
confirming the role of NALP3 and inflammasome in AdV-induced innate immune response 
(Muruve et al., 2008).  Furthermore, recognition of AdV DNA through endosomally 
expressed TLR9 upregulated expression of NALP3, ASC and pro-IL-1ǃ thereby tuning the 
cellular environment for a stronger IL-1ǃ response.(Barlan et al., 2011) 
2.2 AdV interactions with blood factors 
In addition to immune responses, successful gene therapy will depend on organ specific 
delivery and an adequate expression level of the gene of interest. Following intravascular 
delivery, AdV vectors first come in contact with blood and its components. Considering the 
diverse cell types and myriad of proteins with roles in processes as complex as immune 
response, coagulation, cell signaling and others, it is not surprising that interactions between 
AdV vectors and blood components are pivotal in shaping the biodistribution profile of 
intravascularly delivered AdV and, also, the complexity of the ensuing host immune 
response (Parker et al., 2008). Therefore, a thorough understanding of AdV and blood factor 
interactions is advantageous in devising novel strategies to preclude deleterious interactions 
and to efficiently target vector delivery to the organ. 
Based on in vitro experiments, the classical pathway for AdV internalization involves a 
primary interaction of fiber knob domain with Coxsackievirus and adenovirus receptor 
(CAR) resulting in viral attachment to cell surface, followed by a secondary interaction of 
the RGD motif on a penton base with integrins promoting internalization of the attached 
virus via receptor-mediated endocytosis. However, the in vivo biodistribution pattern cannot 
be attributed to knob-CAR interaction alone since CAR follows a ubiquitous expression 
profile, whereas the majority of intravascularly delivered AdV is sequestered primarily in 
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the liver. Further, HAdV5 vectors modified by inserting retargeting peptides and ablated for 
CAR binding fail to efficiently retarget to intended sites (Nicklin et al., 2005). These 
observations suggest involvement of CAR-independent pathways of cellular transduction in 
vivo by AdV. Heparan sulfate proteoglycans (HSPG) and LDL receptor-related proteins 
(LRP) were identified as alternative receptors for AdV transduction of liver cells. Initially, 
the blood coagulation factor IX and complement factor C4BP were shown to bind to HAdV5 
and HAdV35 fiber knobs and bridge them to HSPG and LRP, thereby providing a ‘CAR-
independent’ pathway of AdV infection in vivo.  
Transduction of Kupffer cells which sequester the majority of the AdV transducing the liver is 
CAR-independent; hepatocytes rely on CAR-dependent, as well as CAR-independent, 
pathways for AdV uptake (Shayakhmetov et al., 2005).  Consequently, abrogation of the factor 
IX- and factor C4BP-mediated AdV transduction can be an effective strategy for precluding 
AdV sequestration in Kupffer cells which contributes significantly to a proinflammatory 
cytokine and chemokine response to systemic administration of AdV vectors (Lieber et al., 
1997; Manickan et al., 2006). Preventing Kupffer cell transduction can simultaneously provide 
dual benefits for effective liver gene therapy by mitigating the innate immune response and 
enhancing hepatocyte transduction through greater bioavailability of the vector.  
The Vitamin K-dependent blood coagulation factors FVIII, FIX, FX and protein C also appear 
to play crucial roles in hepatocyte transduction through interactions with the HAdV5 viral 
capsid. Of note, these coagulation factors contain a conserved domain with an identical, 
defined structure comprising of a Ǆ-carboxyglutamate (Gla)-EGF-1-EGF-2-serine protease 
domain which supposedly arose due to gene duplication. All of these factors significantly 
enhance hepatocyte transduction in vitro with factors FX and protein C being more efficient 
than factors FVIII and FIX through mediating interactions between the capsid, and the 
alternate AdV receptors, HSPGs and LRP. Interestingly, the factors did not exert an additive 
effect on transduction as they all seem to bind at a common site on the capsid and, therefore, 
might have an overlapping role in mediating AdV entry. Depletion of vitamin K-dependent 
blood coagulation factors in mice through warfarin treatment prior to intravascular AdV 
administration resulted in a remarkable reduction in hepatocyte transduction. This effect could 
be reversed by restoring physiological levels of factor FX just prior to AdV inoculation (Parker 
et al., 2006). The relevance of factor FX - hexon interaction to AdV vector biology is justified by 
swapping the hypervariable regions (HVRs) of HAdV5 with those from HAdV48, a non-factor 
FX-binding serotype, which absolutely abrogates the interaction and also decreases the 
hepatocyte transduction by more than 150-fold. The interaction between factor FX and the 
capsid hexon is calcium-dependent and mediated by the (Gla)-EGF1 domain of factor FX and 
the HVRs of hexons. No other capsid proteins play any role in the factor FX-capsid interaction. 
Furthermore, the hexon from all human AdV serotypes does not bind factor FX equally; 
serotypes 5, 2, 50 and 16 show strong binding, while serotypes 35 and 3 show weak binding, 
and serotypes 26 and 48 show no binding (Waddington et al., 2008). Construction of hexon 
swapped AdV vectors should be performed accordingly, keeping in mind the factor FX 
binding ability of the serotype and the intended clinical use of the vector. While constructing 
AdV vectors targeted to specific sites, tissue-specific fiber modifications must be accompanied 
by appropriate hexon HVR modifications large enough to ablate factor FX binding yet small 
enough to allow the chimeric virus rescue.  
A recent study suggested that AdV sequestration in the liver is a collective result of a defined 
set of molecular mechanisms occurring in a redundant, sequential and synergistic pathway (Di 
Paolo et al., 2009). In addition to the trapping of intravascular AdV by Kupffer cells and 
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hepatocytes through interactions with blood factors, the AdV penton base-ǃ3-integrin 
interaction becomes predominant in the absence of other virus clearance mechanisms. 
Combined treatment with chlodronate liposomes and warfarin removes Kupffer cells and 
inactivates vitamin K-dependent blood factor, prevents AdV entry into Kupffer cells and 
hepatocytes, and, therefore, might force AdV to accumulate in the liver sinusoidal space.  Here 
the interaction between penton base RGD motif and ǃ3-integrin may promote AdV uptake by 
sinusoidal endothelial cells (Di Paolo et al., 2009). These observations led to the proposal of a 
three step, dose-dependent model of AdV sequestration in the liver. At low doses, Kupffer 
cells are the primary niche for AdV retained in the liver. When the dose is higher and exceeds 
Kupffer cell capacity, the excess AdV enter hepatocytes in a blood factor-dependent manner. 
At an even higher dose, both Kupffer cells and hepatocytes become fully loaded, and AdV 
start entering sinusoidal epithelial cells. Following these principles, complete elimination of  
liver retention of systemically delivered AdV through simultaneous blocking of all three 
mechanisms might enhance the bioavailability of AdV vectors for gene therapy applications of 
extrahepatic organs and preclude induction of innate immune-mediated hepatotoxicity from 
reaching dangerous levels. 
3. Adaptive immune responses to AdV vectors  
AdV vector-mediated transduction in vivo results in efficient but transient transgene 
expression in various organs with the exception of those in newborn, immunocompromised 
or immunodeficient animals. The loss of transgene expression is attributed to a low basal 
level expression of AdV proteins despite the absence of E1A and E1B (Yang et al., 1994). 
Apart from induction of a strong innate immune response, AdV vectors also elicit adaptive 
immune responses directed towards the capsid components. The induction of adaptive 
immunity is profoundly influenced by the activated innate immune response (Descamps & 
Benihoud, 2009). The AdV-specific cellular immune response is induced through the uptake 
of AdV particles by antigen-presenting cells such as macrophages and DCs and the 
presentation of peptides derived from capsid proteins through MHC class I and class II 
pathways. Subsequently, the CTLs recognize and destroy the host cells displaying AdV-
specific peptides, thereby leading to diminished transgene expression in immunocompetent 
hosts (Schagen et al., 2004). Macrophages also play a role in transporting AdV to draining 
lymph nodes, where AdV-specific B lymphocytes are activated resulting in an AdV-specific 
humoral immune response comprising of anti-AdV antibodies directed against capsid 
proteins (Junt et al., 2007).  
The HD-AdV vectors, due to a lack of all viral genes, effectively remain unseen by the 
immune system and consequently cause a severely attenuated adaptive immune response. 
However, a transgene-specific immune response can be induced causing elimination of the 
host cells expressing the target protein in addition to antibody-mediated clearance of 
secreted target protein from circulation. The problem of anti-transgene immunity is unique 
and no less confounding than vector-associated primary complications since immunity may 
vary with the nature of transgene, animal model or even individual (Brown et al., 2004). On 
the positive side, HD-AdV vector-based gene therapy studies in various mouse and rat 
models of diseases such as diabetes, hemophilia, familial hypercholesterolemia, ornithine 
transcarbamylase deficiency, and Crigler Najjar syndrome produced favorable results 
through long-term phenotypic correction implying transgene-specific immunity may not be 
a significant hindrance (Seiler et al., 2007).  
www.intechopen.com
 
Adenoviral Vectors: Potential and Challenges as a Gene Delivery System 99 
3.1 Significance of pre-existing vector immunity 
More than 80% of the human population has been exposed to one or more serotypes among 
over fifty different serotypes of human AdV (Harvey et al., 1999; Xiang et al., 2006). The 
adjuvant effect of AdV results in development of strong anti-viral humoral and cellular 
immune responses in the pre-exposed individuals. These neutralizing antibodies are 
serotype-specific and are directed toward the viral capsid proteins.  Similarly, the AdV-
specific CD8+ T cells against both viral structural and non-structural proteins as well as the 
transgene will eliminate AdV-transduced cells (Tang et al., 2006). In the absence of pre-
existing immunity, re-administration of homologous vector mimics vector administration in 
the presence of pre-existing immunity. Therefore, first and second generation AdV vectors 
are not suitable for correction of disorders requiring multiple vector inoculations and are 
limited to only those applications requiring short-term transgene expression or 
circumvention of vector immunity, either natural or induced. The presence of anti-AdV 
antibodies also enhances AdV uptake by DCs and macrophages via interaction with the Fc-
receptor (FcR), but without a consequent increase in transgene expression. Pre-
immunization with homologous vectors has been shown to exacerbate vector-induced 
hepatotoxicity and increase mortality rates (Vlachaki et al., 2002) which might be the 
indirect consequences of stronger innate immune activation.  
4. Evolution of AdV vector systems 
Despite early observations, it took several years following the advent of recombinant 
technology before the therapeutic potential of AdV was truly realized.   The first 
generation AdV vectors (FGAdV) have a deleted early region (E) 1 (E1).  The E1 region 
has two subunits E1A and E1B (Dormond et al., 2009).  E1A deletions impair vector 
replication, down regulate transactivation of other early units, and deregulate cell cycle 
controls.  However, this deletion does permit transgene expression capacity up to 
5kb.  E1B primarily inhibits apoptotic cell signaling.  Most of these vectors also have a 
deletion in E3, which does not hinder in vitro growth but adds 3kb worth of transgene 
capacity. The different types of AdV vectors are described below and illustrated in  
Figure 1. 
The Frank Graham Laboratory in 1977 developed a human embryonic kidney-derived 293 
cell line that expresses the E1 gene products in trans thereby enabling the production of the 
first recombinant AdV (rAdV) in a helper-free environment (Graham et al., 1977). The 293 
cell line used in vector manufacturing has nucleotides 1-4344 of the left end of the AdV 
genome which provides considerable overlap in the sequences with conventional 
vectors.  These overlapping sequences within the cell promote homologous recombination 
between the vector and the AdV sequences which can generate replication-competent AdV 
(RCAdV) recombinants during the process of amplification.   
Currently, the FDA has ruled that there must be less than one RCA per 3 x 1010 vector 
particles (Jolly et al., 2008). New cell lines, such as PER.C6 (Fallaux et al., 1998) and SL0036 
(Howe et al., 2006), have been developed which abrogate sequence overlap and reduce 
RCAdV occurrence.  Another method to diminish sequence overlap and reduce RCAdV risk 
has been to transfer a protein encoding gene into the cell genome which encodes for pIX, a 
minor AdV capsid protein (Hehir et al., 1996). The introduction of stuffer DNA into the E3 
region is an additional method which increases the FGAdV DNA size but renders the 
system unpackageable in E1-recombined viral DNA progeny. 
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Fig. 1. Representative Diagram of the wild type AdV genome and different deletions in the 
various AdV vector constructs. E1 - E4: early transcription regions; L1 - L5: late transcription 
regions; ITRs: inverted terminal repeats; ψ: packaging signal; mE1: mutated E1;  
TSP: tumor-specific promoter. 
In order to reduce the in vivo toxicity associated with the FGAdV, the second generation 
AdV vectors (SGAdV) were developed with additional deletions in their vector 
constructs.  The initial E1 or E1/E3 deletions are supplemented with full or partial deletions 
in E2 and/or E4.  Complementing cell lines are designed to constitutively express the 
matching E2/E4 region, but isolating these cell lines is a time-consuming process.  The 
propagation of these vector constructs is less likely to generate RCAdV but will also have a 
lower yield.  Although production possesses its own problems, it ultimately limits effects on 
immunogenicity resulting in the loss of interest for these multiple regions-deleted vectors 
(Lusky et al., 1998; Morral et al., 2002; O'Neal et al., 1998).  Ultimately, long term expression 
and added safety were not attained with SGAdV (Dormond et al., 2009). 
The further deletions of viral encoding genes that were gradually introduced to address safety 
concerns gave rise to the third generation AdV vectors (TGAdV).  TGAdV lack all non-
essential viral sequences.  The TGAdV or helper-dependent AdV (HD-AdV) rely on helper-
dependent systems in order to be generated.  Along with the packaging signals, the inverted 
terminal repeats (ITRs) of AdV are required in cis to initiate replication (Grable & Hearing, 
1992). Non-coding stuffer DNA is introduced into the 36kb of space that is available for 
transgene insertion.  Helper functions are furnished by FGAdV which are also referred to as 
helper AdV.  Initially, this class of AdV yielded a low number of TGAdV and a high level of 
contamination from helper AdV (Kochanek, 1999; Mitani et al., 1995). The purification of 
TGAdV from FGAdV by density gradient is a difficult task (Kumar-Singh & Chamberlain, 
1996; Mitani et al., 1995; Parks & Graham, 1997). To facilitate better separation, the size of 
TGAdV should not exceed 32 kb which permits a better separation from the 36 kb FGAdV.   
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A recombinase system has been introduced into the TGAdV platform in order to reduce 
the amount of contamination (Hardy et al., 1997; Lieber et al., 1996; Parks et al., 
1996).  Adding a recombinase recognition site next to the packaging signal of the helper 
AdV yields an unpackageable FGAdV while co-infecting into HEK293 cells that 
constitutively express the respective recombinase.  Currently, three recombinase systems 
have been employed:  (1) Cre/LoxP, (2) FLP/frt and (3) C31/attB-attP (Alba et al., 2007; 
Ng et al., 2001; Umana et al., 2001).  The two latter systems possess similar potential for 
the removal of FGAdV (Ng et al., 2001; Umana et al., 2001). Certain sequences on the 
TGAdV genome influence the yield.  The stuffer DNA that is selected is of non-coding 
human DNA origin with minimized repeating sequences (Parks et al., 1999; Sandig et al., 
2000; Schiedner et al., 2002). A promoter in the E4 region has provided amplification 
enhancement to TGAdV (Sandig et al., 2000). Additional amplification has been 
accomplished by the strategic development of FGAdV (Zhou et al., 2002). Sequence 
homology between packaging signals of the FGAdV and TGAdV should be avoided in 
order to limit the recombination events (Hardy et al., 1997; Sandig et al., 2000).  
Complementary cell lines used in the production of TGAdV were derived from those that 
produce FGAdV and SGAdV.  Furthermore, these cell lines express the respective 
recombinase enzyme such as Cre, FLP, or C31 (Alba et al., 2007; Ng et al., 2001; Umana et al., 
2001). Generating competent cell lines that amplify TGAdV, while limiting FGAdV 
contamination has been difficult.  Investigators have demonstrated that FGAdV 
contamination is due to the AdV-mediated shutoff of the host cell (Hartigan-O'Connor et al., 
2002). The appearance of RCAs in TGAdV preparations has been attributed to a low level of 
FGAdV serving as helper AdV.  Yet, production methods that necessitate that two viral 
constructs be present during serial passages increases the incidence of RCA.  The use of 
PERC.6, a cell line which minimizes homology (Sakhuja et al., 2003), and the addition of 
stuffer DNA into the E3 region of FGAdV DNA (Parks et al., 1996) which limits 
encapsidation are useful solutions to minimizing RCAs. 
Some AdV constructs have been changed to focus on the targeting potential instead of 
deleting multiple regions. Various methods are based on the rationale of expanding the 
otherwise limited tropism of the AdV while also reducing the potential toxicity seen in non-
target tissue during over expression thereby improving the odds for systemic 
delivery.  There are two approaches used in targeting:  the modification of the virion to 
specifically transduce targeted cells or the use of gene regulation to restrict transgene 
expression to desired tissues.  Tissue restriction modifications can be accomplished by 
genetically modifying the fiber-knob structure or through the covalent binding of a 
“bridging” molecule to the virion (Fattori et al., 2006; Folgori et al., 2006; Gherardi et al., 
2003; Heeney et al., 2000; Lemckert et al., 2005; Liu et al., 2009; Shiver et al., 2002; Yu et al., 
2008). Modification possibilities are limitless and range from the addition of de novo 
peptides or fiber-knob hybrids that combine other human and nonhuman AdV to 
exploitation of common receptor-ligand interactions to variations in RGD or similar motifs 
(Jolly et al., 2008). The bridging molecule method is advantageous since multiple antibodies 
and ligands can be implemented to form bispecific (target and AdV) bridges between the 
vector and the target cell type.  Despite the advantages, each bispecific molecule and virion 
combination will possess unique effects, distribution, and toxicity profiles which will have 
to be defined both individually and as a constituent of a biological complex used in clinical 
data for drug trials. Retargeted or unique serotype vectors may prove efficacious in 
bypassing anti-vector immunity which could otherwise disturb transgene delivery used in 
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vaccine applications.  Promising preclinical data with canine and nonhuman primate AdV 
exists (Alejo et al., 2006; Beveridge et al., 2007; McElrath et al., 2008). 
Transcriptional targeting is achieved by placing a gene of interest under the control of a 
tissue- or tumor-specific promoter.  This construct possesses potential for desired long term 
gene expression especially when small levels of expression in nontargeted cells can 
significantly impact potency or toxicity.  One of the first constructs implemented in a human 
lung cancer cell line used the carcinoembryonic antigen promoter (CEA) to drive expression 
of the thymidine kinase gene derived from the herpes simplex virus (Liu et al., 2008a).  
Other promoters have been used which possess similar efficacy while simultaneously 
reducing the vector toxicity (Geiben-Lynn et al., 2008; Jego et al., 2003).  
Conditionally replicating AdV vectors (CRAdV) have been implemented in cancer 
therapeutics because lysis of solid tumor masses requires a replicating vector in order to 
penetrate and spread through the tumor cells (Everts & van der Poel, 2005). The first class of 
deletion mutant CRAdV was designed so that a portion of E1 remains intact. Either E1A or 
E1B are mutated in order to confer replicative capacity only in human tumor cells which 
possess an impaired retinoblastoma tumor suppressor (Rb) or p53 gene.  The second class of 
CRAdV possesses a tissue specific promoter upstream of E1A which restricts replication 
only in the target cells.  Class 1 and 2 CRAdV have been adequately produced in E1-
containing cell lines.  RCAdV-preventing cell lines such as HeLA or A549 have also been 
implemented in CRAdV production (Longley et al., 2005; Yuk et al., 2004). 
5. AdV vectors as a gene therapy tool 
One of the important applications of gene therapy is the treatment of patients with monogenic 
recessive disorders by delivery of the mutated or non-functional gene. Hemophilia, cystic 
fibrosis and muscular dystrophies are some of the several thousand inherited disorders that 
can, in principle, be corrected by gene therapy. The various techniques used for delivery of 
therapeutic genes include viral vectors, physical methods, chemical methods and naked 
nucleic acids.  A successful gene therapy program requires an efficient gene delivery system 
and targeting of a specific cell type without dissemination of the therapeutic gene to other cells 
thereby allowing longer persistence and adequate expression of the replaced gene. In the case 
of viral vectors, the host immune response may become a significant barrier to gene delivery 
and impede the overall success of the gene therapy effort.   
AdV-based vectors were initially thought to be very promising candidates for gene therapy 
applications for genetic disorders. However, the progress of AdV vectors have been 
hampered by vector immunity and the toxicity induced by AdV vectors following systemic 
administration. The pre-existing anti-AdV neutralizing antibodies in the majority of the 
human population induced following natural exposure to AdV clears the AdV vectors soon 
after systemic administration. In the absence of pre-existing anti-AdV antibodies, the AdV 
vectors persist longer following initial inoculation. Repeated administration results in 
development of a neutralizing antibody response similar to natural infection preventing 
subsequent inoculations with the same vector from being effective.  
The death of the patient in the ornithine transcarbamylase (OTC) clinical trial (Raper et al., 
2003) and the results of several subsequent pre-clinical trials shifted the focus of AdV 
research towards the molecular mechanisms underlying AdV-induced innate immune 
pathways leading to development of AdV vectors, such as HD-AdV vectors, particularly 
suited for gene therapy applications. These HD-AdV vectors, due to the deletion of most of 
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the viral genome, can accommodate inserts as large as 36 Kb, making them the vector of 
choice for delivering very large genes, multiple genes or ta tissue-specific regulatory 
promoter which may be very long (Shi et al., 2002; Shi et al., 2006). The host cells transduced 
by HD-AdV vectors do not express the viral proteins and, therefore, cells carrying HD-AdV 
are not recognized by the host immune system resulting in longer persistence and transgene 
expression. 
5.1 HD-AdV for liver gene therapy 
The liver is the most affected organ in several genetic diseases including Crigler-Najjar 
syndrome and OTC deficiency. HD-AdV vectors have shown tremendous promise for liver 
directed gene therapy in several pre-clinical studies in small and large animal models.   
Their abilities to support long-term transgene expression, low chronic toxicity, natural  
liver tropism of AdV vectors and the fenestrated structure of liver endothelium  
allowing efficient hepatocyte transduction are the main factors (Brunetti-Pierri et al., 2008; 
Dimmock et al., 2011; Toietta et al., 2005). HD-AdV vectors were shown to be very effective 
for liver gene therapy in Gunn rats, the animal model for Crigler-Najjar syndrome. A single 
injection of a HD-AdV vector expressing uridine diphospho-glucuronosyl transferase 1A1 
(UGT1A) was sufficient to induce life-long normalization of hyperbilirubinemia (Toietta et 
al., 2005). Similarly, an HD-AdV vector expressing canine glycogen-6-phosphatase was able 
to correct the hypoglycemia and prolong survival up to seven months in a mouse model of 
glycogen storage disease type 1 (Koeberl et al., 2007). Results of several other studies have 
supported the clinical utility of HD-AdV vectors in the gene therapy of liver diseases 
(Brunetti-Pierri et al., 2008; Gau et al., 2009; Hu et al., 2011; McCormack, Jr. et al., 2006; Oka 
et al., 2007). 
However, the prospects of liver directed gene therapy using HD-AdV vectors are hampered 
by the high vector doses necessary to result in efficient hepatocyte transduction. Such high 
doses may not be clinically relevant for human use. A non-linear relation is observed between 
the vector dose and hepatocyte transduction; at low doses, there is very little to undetectable 
transgene expression, yet there are disproportionately high levels of transgene expression 
when vector dose is increased (Morral et al., 2002; Sullivan et al., 1997) with the Kupffer cells 
sequestering more than 85% of the intravascularly administered AdV vectors. AdV vectors 
also associate with platelets, red blood cells and other binding components in circulation 
resulting in eventual elimination of the vector. Sequestration by Kupffer cells and binding to 
the blood components determines the ‘threshold dose’ which must be administered for 
efficient hepatocyte transduction. Unfortunately, such high doses precipitate acute toxicity due 
to activation of the innate immune system and might result in the death of patient as observed 
during the human clinical trial for gene therapy of OTC deficiency (Raper et al., 2003). This 
conundrum warrants a thorough understanding of mechanisms underlying AdV-mediated 
innate immune system induction and calls for development of novel strategies to achieve high 
level hepatocyte transduction at clinically relevant doses.  
5.2 HD-AdV for brain gene therapy 
Due to the complexity of tissue organization in the nervous system, treatment of 
neurological disorders imposes a huge challenge to both healthcare providers and clinical 
researchers alike.  HD-AdV gene therapy is currently being employed in preclinical trials as 
well as in animal models in the cases of brain cancer, sensory neuronopathies, 
neurodegenerative diseases, and multiple sclerosis, to name a few. Despite pre-exposure to 
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AdV, the sustained transgene expression in the brain for at least one year (Barcia et al., 2007) 
and the ability to infect the cells of the central nervous system renders HD-AdV vectors 
particularly appealing for brain gene therapy. 
5.2.1 Gliomas  
The tumor originating from glial cells is called a glioma which is highly lethal and 
associated with a median survival of mere 9-12 months (Furnari et al., 2007). Among 
gliomas, Glioblastoma multiforme (GBM) is the most common and so far incurable; 
aggressive primary brain cancer in adults has a median survival time of 15-21 months 
(Grossman et al., 2010). GBM is highly invasive with a limited potential for complete 
resection and a high recurrence rate owing to its resistance towards conventional 
chemotherapy and radiotherapy. A combination of HD-AdV-TK (cytotoxic herpes simplex 
type 1 thymidine kinase/HSV1-TK) and HD-AdV vector encoding Flt3L (human soluble 
fms-like tyrosine kinase ligand 3) under the control of a tightly regulatable mCMV-TetOn 
expression system (HC-AdV-TetOn-Flt3L29–31) was tried in rats bearing GBM (Muhammad 
et al., 2010). As a result of intratumoral administration of HD-AdV vectors, tumor cells were 
rapidly removed from the brain, and ~70% of the animals showed a reduction in the tumor 
mass within thirty days of the treatment leading to a long-term survival rate. The treatment 
also ensured the safety of the protocol with a one-year follow-up indicating the lack of 
behavioral deficits, chronic inflammation in the brain or alteration in the brain architecture. 
Furthermore, in order to lower the vector dose and improve production yield, a bi-cistronic 
HD-AdV vector has been developed “that encodes both constitutively expressed HSV1-TK 
and inducible Flt3L from a single HD-AdV vector genome” - the first one of its kind (Puntel 
et al., 2010).  
5.2.2 Sensory neuronopathies 
Dorsal root ganglion (DRG) neuron dysfunction is commonly associated with a number of 
sensory neuronopathies, and therefore, DRG comprises the target of choice for their 
treatment. Undesirable side effects of conventional treatments can be minimized by targeted 
gene delivery towards DRG neurons (Waehler et al., 2007). Fiber modified HD-AdV vectors 
have been engineered to specifically target DRG neurons in mice (Terashima et al., 2009) 
and were also tested in Hexb–/– mice, an animal model exhibiting neurological impairment 
leading to death before the age of twenty weeks (Sango et al., 2002). DRG-targeted HD-AdV 
vectors were injected through an intra-thecal route and were shown to have a significantly 
higher transduction of DRG neurons compared to unmodified HD-AdV vectors. Testing in 
Hexb–/– mice also showed production of ǃ-hexosaminidase in the original Hexb-deficient 
mice as well as a reversal of gangliosidosis and improvement in peripheral sensory 
dysfunction (Terashima et al., 2009).   
5.2.3 Neurodegenerative diseases 
A helper-dependent canine AdV (CAdV-2) vector was designed and tested by Soudais et al 
(2003) and was proposed to be useful in the treatment of neurodegenerative diseases 
(Soudais et al., 2004).  The advantages associated with this particular vector include 
preferential transduction of the neurons and retrograde transportation through the axons. 
Due to the chronic nature of neurodegenerative diseases, it is of particular interest whether 
the treatment can be offered over a long period of time. HD-AdV vectors have been 
administered into the cerebrospinal fluid (CSF) of non-human primates through lumbar 
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puncture, and it was shown that the intervention allowed a long-lasting (three months) 
infection of the neuroepithelial cells without any systemic or local toxicity (Butti et al., 2008).  
5.2.4 Multiple sclerosis 
The ability of HD-AdV vectors to express anti-inflammatory molecules can be useful in 
inflammatory disorders of the central nervous system. Experimental autoimmune 
encephalomyelitis (EAE) is an animal model of multiple sclerosis that has been adopted for 
pre-clinical studies. HD-AdV vectors expressing IL-4 were administered into the CSF of 
immunocompetent mice that allowed transduction of neuroepithelial cells and prolonged 
(five months) transgene expression without any adverse effects (Butti et al., 2008). 
6. AdV vectors for cancer therapy 
Not long after the discovery of existence of AdV, AdV were noted for their oncolytic  
nature in the clinical treatment of cervical carcinoma. Since that time, AdV have shown 
promise in the cancer vaccine field and currently offer a variety of methodologies which are 
being implemented to combat various forms of cancer (Table 1). The field of cancer 
vaccinology is fraught with complications since an effectively persistent immune response 
must be stimulated.  One complication lies in the fact that immune tolerance must be 
overcome against self-antigens.  These self-antigens, which are weak stimulators of the 
immune system or completely lack the ability to be immunogenic in an 
immunocompromised environment, pose quite a hurdle in the cancer vaccine 
development.   
 
AdV Condition Intervention 
Route of 
Inoculation 
Phase Sponsor 
Cancer 
Replication defective AdV5 
[E1-, E2b-]-CEA(6D) [ETBX-011] 
Advanced or 
metastatic 
malignancies 
expressing CEA 
(colon cancer, lung 
cancer, breast cancer) 
Biological: Ad5 CEA 
Vaccine 
s.q. I Etubics Corp. 
Replication defective, 
Adv/CMV.rhENDO 
(AdVE10A) 
Head and Neck 
Squamous 
Carcinoma 
Nasopharyngeal 
Carcinoma 
Drug: E10A Drug: 
Cisplatin  Drug: Paclitaxel 
i.t. II 
Sun  
Yat-sen 
University 
Replication defective  
E1-,E3-deleted HAdV5/CD40L 
gene driven by RSV promoter 
Bladder cancer Genetic: AdCD40L Intravesical I / II 
Uppsala 
University 
E1a and E1b-deleted CRrAdV5-
p53 (SCH-58500) 
recurrent, or 
progressive 
glioblastoma 
multiforme, 
anaplastic 
astrocytoma, or 
anaplastic mixed 
glioma 
Biological: recombinant 
adenovirus-p53 SCH-
58500 
i.t. I 
National 
Cancer Institute 
(NCI) 
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AdV Condition Intervention 
Route of 
Inoculation 
Phase Sponsor 
Infectivity enhanced 
CRAdV5/tk (GliAtak) 
(PancAtak) (ProstAtak) 
malignant glioma, 
glioblastoma 
multiforme, 
anaplastic 
astrocytoma, 
pancreatic cancer, 
prostate cancer 
Biological: AdV-tk Drug: 
Valacyclovir  + Standard 
Chemo-/Radio- therapy 
i.t. II 
Advantagene 
Inc. 
Replication defective 
E1a/E1b/E3 HAdV5.IL2 into 
autologous neuroblastoma cells 
Neuroblastoma 
Biological: autologous 
neuroblastoma vaccine 
s.q. I / II 
Baylor College 
of Medicine 
AdV.IFNgamma (TG1042) 
Relapsing primary 
cutaneous B-Cell 
Lymphoma 
Genetic: Adenovirus 
Interferon gamma 
intralesional II Transgene 
Replication-defective E1/E3-
deleted AdVHer2/neu under 
the control of MMTV promoter 
transduced into DC 
breast neoplasm 
Biological: CD34+ derived 
DCs 
intradermal I 
Hamilton 
Health Sciences 
Corporation 
E1/E2a/E3-deleted HDAdV 
expressing rat Her2/neus 
metastatic breast 
cancer, recurrent 
breast cancer 
Biological: adenoviral 
vector encoding rat Her-
2/neu 
intradermal I 
Ontario Clinical 
Oncology 
Group (OCOG) 
Replication deficient, E1/E3 
deleted rAdV/RSV-hIL12 gene 
primary metastatic 
breast cancer spread 
to liver 
Biological: adenovirus-
mediated human 
interleukin-12 
i.t. I 
Mount Sinai 
School of 
Medicine 
Replication-incompetent Ad-
sig-hMUC-1/ecdCD40L vaccine 
MUC-1 positive 
cancer cells in 
metastatic breast 
cancer 
Biological: Ad-sig-hMUC-
1/ecdCD40L vaccine 
s.q. I 
University of 
California, Los 
Angeles 
Replication defective, 
recombinant Ad.hIFNbeta gene 
Colorectal carcinoma 
metastases 
Drug: Ad.hIFNbeta 
(BG0001, IDEC-201) 
i.v. I / II Biogen Idec 
Replication-deficient (E1, E3 
and E4 deleted) AdV 
containing TNF-alpha gene 
under control of radiation 
inducible promoter 
Esophageal cancer Genetic: TNFerade i.t. II GenVec 
Replication-deficient E1/E3 
deleted rAdcuCD40L 
Esophageal 
neoplasms 
Genetic: AdcuCD40L i.t. I / II 
Weill Medical 
College of 
Cornell 
University 
(INGN 201) 
(Advexin®)HAd5CMV/p53 
Head and Neck 
Cancer:  
premalignant 
carcinoma of the oral 
cavity or pharynx 
Biological: Ad5CMV-p53 
gene 
oral rinse I / II 
M.D. Anderson 
Cancer Center 
HAd5F35.LMP1/LMP2-DC 
Head and Neck 
Cancer: metastatic 
nasopharyngeal 
cancer 
Biological: Ad5F35-
LMP1/LMP2-transduced 
autologous DC Drug: 
celecoxib 
intradermal II 
NCC Head and 
Neck Clinic 
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AdV Condition Intervention 
Route of 
Inoculation 
Phase Sponsor 
Replication defective AdV 
w/TK, TK99UN suicide gene 
therapy 
Carcinoma, 
hepatocellular 
Genetic: TK99UN i.t. I 
Instituto 
Cientifico y 
Tecnologico de 
Navarra, 
Universidad de 
Navarra 
AdVhAFP 
Locoregionally pre-
treated 
hepatocellular 
carcinoma 
Drug: AFP + GM-CSF 
Plasmid Prime and 
AdV/hAFP  Boost 
i.m. I / II 
University of 
Pittsburgh 
AdV.p53-DC 
Extensive Stage 
Small Cell Lung 
Cancer 
Biological: Autologous DC 
transduced w/ AdVp53 + 
chemo Drug: w/ or w/o 
all trans retinoic acid 
(ATRA) 
intradermal II 
H. Lee Moffitt 
Cancer  
Center and 
Research 
Institute 
E1b 55kD-, E3- HAdV5/RSV-
TK 
Cutaneous 
Metastatic Malignant 
Melanoma 
Biological: adenovirus 
RSV-TK Drug: ganciclovir 
Intra-lesional I 
National 
Human 
Genome 
Research 
Institute 
(NHGRI) 
Replication-defective 
AdV.IFNalpha gene 
Malignant Pleural 
Mesothelioma 
Drug: SCH 921015 + 
chemotherapy 
intrapleural 
infusion 
0 
Abramson 
Cancer  
Center of the 
University  
of Pennsylvania 
Replication-defective 
AdV.TNFalpha  
controlled by  
chemoraditation  
inducible promoter 
unresectable locally 
advanced pancreatic 
cancer. 
Genetic: TNFerade    5-FU i.t. III GenVec 
CRhAdV5/SSTR/TK.RGD 
(imaging gene/infectivity 
enhanced suicide gene) 
ovarian cancer 
Genetic: 
Ad5.SSTR/TK.RGD Drug: 
Ganciclovir (GCV) 
Intra-
peritoneal 
I 
University of 
Alabama at 
Birmingham 
Replication defective 
AdVhIL12 
prostatic neoplasms 
prostate cancer 
Genetic: Il-12 gene 
prostatic 
injection 
I 
Baylor College 
of Medicine 
Ad-REIC/Dkk-3 Prostate cancer 
Biological: Ad-REIC/Dkk-
3 
prostatic 
injection 
I 
Momotaro-
Gene Inc. 
Replication competent AdV5-
yCD/mut TKSR39 rep-ADP 
Prostate cancer 
Biological: Ad5-
yCD/mutTKSR39rep-ADP 
Radiation: IMRT 
prostatic 
injection 
II / 
III 
Henry Ford 
Health  
Systems 
Gene Therapies 
Replication deficient 
AdGVVEGF121cDNA 
Coronary Artery 
Disease 
Genetic:  
AdGVVEGF121cDNA 
Intra-
myocardial 
FU 
on 
Phase 
I 
Weill Medical 
College of 
Cornell 
University 
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AdV Condition Intervention 
Route of 
Inoculation 
Phase Sponsor 
Replication deficient E1, E4 
deleted HAdV5OTCcDNA 
Ornithine 
Transcarbamylase 
Deficiency Disease 
Genetic: AdV Vector-
Mediated Gene Transfer 
Femoral 
arterial 
placement of 
a hepatic 
intraarterial 
catheter 
I 
FDA Office of 
Orphan 
Products 
Development 
Replication deficient E1 
deleted rHAd5-CB-CFTR 
Cystic Fibrosis Genetic: Ad5-CB-CFTR nasal cavity I 
National Center 
for Research 
Resources 
(NCRR) 
E1 deleted, E3 substituted 
(d1309) AdV5/OTC 
Amino Acid 
Metabolism, Inborn 
Errors 
Behavioral: Protein and 
calorie controlled diet 
i.v. I 
National Center 
for Research 
Resources 
(NCRR) 
 Replication deficient, E1, E3 
and E4 deleted, AdV/PEDF 
(pigment epithelium-derived 
factor) protein 
Macular 
Degeneration 
Drug: AdGVPEDF.11D 
intravitreal 
injection into 
one eye 
I GenVec 
Replication deficient deleted 
for all of E1a, most of E1b, and 
E3 sequences AdV/VEGF-D 
gene  and a biodegradable local 
delivery device (collar) made of 
collagen 
End Stage Renal 
Disease 
(RAVE trial) Procedure: 
Graft placement surgery 
plus Trinam therapy 
Near anasto-
mosis 
III 
Ark 
Therapeutics 
Ltd 
Replication deficient,  E1-,E3-
deleted AdV5/PDGF-B 
Varicose Ulcer Drug: Ad5/PDGF-B 
intra-ulcer 
injection 
I 
National 
Institute of 
Arthritis and 
Musculoskeletal 
and Skin 
Diseases 
(NIAMS) 
Replication-deficient 
AdV/VEGF-D 
Angina Pectoris 
Myocardial 
Infarction 
Biological: VEGF-D gene 
transfer 
endocardial 
injection 
system 
I 
Kuopio 
University 
Hospital 
Replication-defective E1 
deleted HAdV5/hAQP1 
Parotid Salivary 
Dysfunction 
Gene Transfer Drug: 
AdhAQP1 
catheter into 
parotid 
I 
National 
Institute of 
Dental and 
Craniofacial 
Research 
(NIDCR) 
Infectious Diseases 
Mix of 2 Replication-deficient, 
recombinants (Ebola-rAd5) 
encoding GP from Zaire and 
SudanGulu strains 
Ebola Hemorrhagic 
Fever 
Drug: VRC-EBOADV018-
00-VP 
i.m. I 
National 
Institute of 
Allergy and 
Infectious 
Diseases 
(NIAID) 
ADhVN1203/04.H5 Pandemic Influenza 
Pandemic Influenza  
Vaccine 
Oral 
ingestion of 
enteric 
capsule 
I Vaxin Inc. 
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AdV Condition Intervention 
Route of 
Inoculation 
Phase Sponsor 
Replication-Competent, 
recombinant AdV4/H5N1 (Ad4-
H5-Vtn) 
Avian Influenza Biological: Ad4-H5-Vtn 
Oral 
ingestion of 
enteric 
capsule 
I PaxVax, Inc. 
Live, Replication-deficient 
rAdV35 (E1-, partially  
deleted E3encoding  
fusion protein of the 
Mycobacterium tuberculosis 
antigens 
Tuberculosis Biological: AERAS-402 i.m. I / II 
Aeras Global 
TB Vaccine 
Foundation 
Replication incompetent, 
multiclade rAdV5 VRC-
HIVADV014-00-VP 
HIV 
Biologicals: VRC-
HIVDNA016-00-VP; VRC-
HIVADV014-00-VP; VRC-
DILUENT013-DIL-VP; 
VRC-HIVADV014-00-VP 
placebo 
i.m. via 
Bioinjector 
I / II 
National 
Institute of 
Allergy and 
Infectious 
Diseases 
(NIAID) 
AdV.ZFN/CCR5 (SB-728-T) HIV 
Biological: ZFN modified 
T cells 
Infusion of 
apheresed T 
cells 
I 
University of 
Pennsylvania 
Replication defective MRK 
Ad5 HIV-1 gag 
HIV 
Biological: MRK Ad5 HIV-
1 gag vaccine 
i.m. II 
National 
Institute of 
Allergy and 
Infectious 
Diseases 
(NIAID) 
rAd26.ENVA.01 HIV 
Biologicals: 
Ad26.ENVA.01 (rAd26); 
Placebo Vaccine 
i.m. I 
National 
Institute of 
Allergy and 
Infectious 
Diseases 
(NIAID) 
rAd35, rAd5 HIV 
DNA Vaccine;  DNA 
Vaccine placebo;  rAd35;  
rAd35 placebo;  rAd5;  
rAd5 placebo 
i.m. I 
National 
Institute of 
Allergy and 
Infectious 
Diseases 
(NIAID) 
rAd5 HIV 
Biological: NYVAC-B 
(poxvirus) 
Biological: Placebo 
Biological: rAd5 
i.m. I 
HIV Vaccine 
Trials Network 
Replication defective simian 
Ad 
HIV 
Biological: 
MVA.HIVconsv low dose 
Other: Placebo low dose 
Biological: 
MVA.HIVconsv high  
dose 
Other: Placebo high dose 
i.m. I 
University of 
Oxford 
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AdV Condition Intervention 
Route of 
Inoculation 
Phase Sponsor 
Ad26.ENVA.01, Ad35-ENV HIV 
Biological: Ad35-ENV 
vaccine 
Biological: Ad26.ENVA.01 
vaccine 
Biological: Placebo Control 
i.m. I 
International 
AIDS Vaccine 
Initiative 
DC=dendritic cell; h=human; LMP= latent membrane protein; PEDF = pigment epithelium-derived 
factor protein; OTC:  ornithine transcarbamylase; r=recombinant; VEGF=Vascular Endothelial Growth 
Factor D; SSTR=somatostatin receptor type 2 
Table 1. Clinical Trials of AdV vectors 
6.1 Tumor suppressor therapies 
Several genes (p53, Rb,BRCA1, PTEN, etc) regulate the cell cycle and apoptotic 
pathways.  The cellular machinery can inhibit tumor formation by suppressing aberrant 
cellular proliferation.  Several malignancies have a loss-of-function mutation in one or more 
of the cell cycle control genes. Gene delivery can rescue a cell from a tumor phenotype by 
restoring the dysfunctional gene or a tumor-suppressor gene.  One of the most extensively 
studied tumor suppressor genes, p53, is mutated in more than 50% of all human 
malignancies.  The administration of wild-type p53 through gene transfer with a replication-
defective AdV has demonstrated significant tumor suppression (Roth, 2006). The repair of 
p53 activity also has impaired angiongenic activity, inhibited the growth of nontransduced 
cells and directed a local immune response against tumor cells.  In addition, replacement of 
p53 increased the vulnerability of tumor cells to chemotherapy and radiotherapy by 
reestablishing pro-apoptotic pathways.  Furthermore, the potency of an anti-tumor response 
is enhanced when p53 gene replacement therapy is supplemented with available cytotoxic 
chemotherapeutics (El-Deiry, 2003). The first AdV gene therapy construct for the treatment 
of cancer has been approved by the State Food and Drug Administration (SFDA) of 
China.  This AdV construct contains a p53 expression cassette in the deleted E1 region and 
has demonstrated remarkable synergistic effects when combined with radio-
/chemotherapy, surgery, or hyperthermia for the management of cancer (Peng, 2005). 
Another way to inhibit tumor growth is to manipulate ligand-receptor interactions. AdV 
have been engineered to deliver ligands to oncogenic receptors in the form of antibodies 
against the receptor or by mimicking natural interactions.  Peptides with either natural or 
recombined ligand moieties have been particularly efficacious in receptor-ligand mimicry 
(Pasquale, 2010).  Receptor-ligand interactions typically lead to down-regulation of that 
receptor either directly or through signal transduction complexes.  One example is the 
EphA2 receptor, a tyrosine kinase protein, which is elevated in breast (Zelinski et al., 2001), 
prostate (Walker-Daniels et al., 1999), pancreatic, (Van Geer et al., 2010) and many other 
cancers.  Thus, EphA2 is a good therapeutic candidate for treating cancer.  Under normal 
conditions, the EphA2 receptor is localized at intracellular junctions where it binds to its 
membrane-anchored ligand, EphrinA1, resulting in phosphorylation of the receptor.  E-
cadherin, a cell adhesion molecule, is also able to phosphorylate EphA2 and aid in proper 
localization of the receptor.  In many cancer cells, EphA2 is over expressed, 
unphosphorylated and unable to bind to its ligands due to its altered localization (Kinch & 
Carles-Kinch, 2003; Zantek et al., 1999).  Monoclonal antibodies directed against EphA2 have 
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been used in order to mimic ligand-induced downregulation.  These antibodies caused 
elevated levels of EphA2 phosphorylation which encouraged its degradation (Carles-Kinch 
et al., 2002). AdV-mediated delivery of the secretory form of EphrinA1 produced 
autophosphorylation, degradation, and subsequent inhibition of tumor growth and 
metastasis (Noblitt et al., 2004; Noblitt et al., 2005).  Likewise, AdV-mediated antibodies 
directed against ErbB2 (HER2/neu) demonstrated that ErbB2 down-regulation increased 
apoptosis and cytotoxicity both in vitro and in vivo (Arafat et al., 2002; Jiang et al., 2006). 
6.2 CRAdV therapy 
An effective approach to cancer therapy is the use of RCAdV that selectively replicate inside 
a tumor and ultimately kill tumor cells while leaving normal cells intact.  As previously 
mentioned, therapeutic CRAdV are either engineered by deletion mutagenesis or 
engineered for the tumor- or tissue-specific replication by use of transcriptional regulatory 
elements (TREs). 
6.2.1 Deletion mutation of CRAdV 
CRAdV have expanded our knowledge regarding AdV proteins and how they interact with 
cellular proteins.  E1 proteins of AdV adjust cell cycle controls in order to promote virus 
replication.  The product of the E1A gene binds to the wild type Rb protein which causes the 
release and activation of E2F, a transcription factor (Whyte et al., 1988). Once E2F is 
activated, the transcription of S phase entry genes facilitates the hijacking of cellular 
machinery involved in AdV replication (Flint & Shenk, 1997).  Additionally, E2F 
transactivates the p14ARF gene which increases p53 levels within the cell by inhibiting its 
degradation by murine double minute 2 (MDM2) (Bates et al., 1998).  Although increased 
p53 levels can cause cellular apoptosis or arrest of the cell cycle, it also inhibits viral 
replication.  To circumvent this replication inhibition, AdV E1B 55 kDa proteins work with 
E4 open reading from (ORF) 6 to bind to p53 and inactivate it preventing apoptosis and 
permitting virus replication and spread (Dobner et al., 1996; Yew & Berk, 1992).  A bcl-2-
related protein, E1B 19 kDa,  also prevents apoptosis stimulated by E1A (Boyd et al., 1994; 
Rao et al., 1992). This knowledge combined with known tumor suppressor genes (i.e., p53 
and Rb), tumor-associated antigens (CEA) or specialized promoters has facilitated the 
development of efficacious CRAdV. 
The first CRAdV to enter clinical trials was ONYX-15 (also known as dl1520), a E1B 
55kDa/E3B deleted vector.  This mutant CRAdV selectively replicates in cancer cells that 
possess a defective p53 while leaving cells with intact p53 alone.  It has undergone 
numerous clinical trials (Phase I to III) to test its therapeutic potential in head and neck 
squamous cell carcinoma, glioblastoma, hepatocellular carcinoma, colorectal carcinoma, 
sarcomas, ovarian, pancreatic, and hepatobiliary cancer (Aghi & Martuza, 2005; Kirn, 2001). 
Data indicate that ONYX-15 is safe and selective for cancer (Kirn & Thorne, 2009), but the 
strategy has failed to demonstrate extensive therapeutic effects or significant systemic 
spread (Liu et al., 2008b). Other oncolytic vectors that possess the same E1B/E3B mutations 
have exhibited the same capabilities, but only H101 was finally approved by the Chinese 
SFDA  for use in combination with chemotherapy to treat late-stage refractory 
nasopharyngeal cancer (Kirn et al., 2008; Liu et al., 2008b). 
There is a weak correlation between p53 status and cellular susceptibility to E1B/E3B 
mutant CRAdV (Geoerger et al., 2002; Hay et al., 1999; Rothmann et al., 1998).  Some 
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researchers have observed that when E1B 55kDa binds to p53, AdV-mediated death is 
followed by a productive infection (Dix et al., 2000; Hall et al., 1998). Others argue that the 
preferential killing by ONYX-15 types may be due to infectivity variances of the vector, 
permissiveness, upregulation of AdV early proteins (Steegenga et al., 1999), p14ARF failure 
(Ries et al., 2000), mutation features of p53 (Hann & Balmain, 2003), or late export of viral 
RNA (O'Shea et al., 2004) rather than solely the status of p53 (Sharma et al., 2009b). 
Replication of ONYX-15 is attenuated when compared with wild-type virus (Dix et al., 2001) 
which may  be attributable to other E1B functions such as translation, nuclear exports of late 
viral mRNA, and compromised inhibition of host cell protein synthesis (Babiss & Ginsberg, 
1984).  Other mutations have been identified in the E1B 55 kDa protein that enhanced 
selectivity for tumors without hindering  viral replication (Shen et al., 2001). 
An alternative method involves the use of CRAdV mutants that possess a deletion in E1A 
and Rb-binding domain (CR-2) which ultimately targets cancers that have aberrant Rb 
pathways (Fueyo et al., 2000; Heise et al., 2000). When anti-tumor potential is compared 
between E1B mutations and CR-2 deletion vectors which do not inhibit vector replication in 
cancerous cells, the CR-2 vectors demonstrate better efficacy in vivo and in vitro (Alemany & 
Curiel, 2001).  There are safety concerns, however, that exist with CR-2 deletion vectors since 
their replication is not restricted to cancer cells alone (Heise et al., 2000).  Incorporation of 
tumor-specific promoters which restrict viral gene expression (i.e., ONYX-411) or the 
incorporation of Arg-Gly-Asp(RGD) motifs are beneficial to enhancing tumor cell selectivity 
and safety (Johnson et al., 2002; Page et al., 2007). 
CRAdV targeting CEA-expressing malignancies in the colon, lung, and breast tissues have 
been successful and are in Phase I clinical trials with HAd5[E1-,E2b-]-CEA(6D) or ETBX-011. 
The HAdV5 has been engineered to express the CEA protein which is found in some 
cancerous cells.  The goal is to direct the immune system to target cancer cells producing 
CEA. [http://clinicaltrials.gov/ct2/show/NCT01147965] 
6.2.2 Transcriptional regulation of CRAdV 
Another class of CRAdV replaces viral promoters that control vital transcriptional units 
with transcription regulating elements (TREs).  Transcriptional targeting drives selection 
according to the vector gene expression and replication parameters set in motion by the 
TREs. The most obvious gene to be selected for TRE regulation is E1A since it is responsible 
for viral replication and adaptations which favor virus replication in the host cell 
environment.  CN706 was the first TRE-regulated AdV to demonstrate potent anti-tumor 
effects (Rodriguez et al., 1997).  In this construct, E1A expression was under the control of 
the prostate-specific antigen (PSA)-derived minimal enhancer/promoter which permitted 
selective replication in PSA-expressing prostate cells.  Several promising TREs under 
investigation today include those that regulate expression of human telomerase reverse 
transcriptase (hTERT), transcription factor E2F, alpha-fetoprotein (AFP), and many more 
which tailor vector replication to be selective for a specific tumor phenotype. 
Leaky replication has been observed in normal cells even though a single essential viral 
gene is under exogenous control.  To improve tumor specificity and safety of CRADV, other 
essential viral genes (e.g., E1B, E2, E4) can be manipulated (Brunori et al., 2001; Doronin et 
al., 2001; Kawashima et al., 2004; Kuppuswamy et al., 2005; Li et al., 2005). A more complete 
list is available in a previous review (Sharma et al., 2009b). Other deletion mutations have 
been made in an effort to exploit specific oncolytic potentials while also retaining the 
replicative capacity of the virus.  However, more work is warranted in all areas of CRAdV 
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development before they can be used commercially.  Additional safety features should 
include external regulation of oncolytic CRAdV through activation of inducible promoter 
systems such as TET or MMTV promoters (Avvakumov & Mymryk, 2002; Chong et al., 
2002; Fechner et al., 2003). Furthermore, tissue-specific promoters can regulate where the 
vector replicates (Hernandez-Alcoceba et al., 2000; Hsieh et al., 2002). Radiation, chemical or 
heat-inducible promoters have also been employed  to restrict transgene expression (Lee et 
al., 2001; Rasmussen et al., 2002). 
Various regulatory elements have been fused in order to artificially design promoters which 
restrict TRE size while also preserving or amplifying rigid control of vector replication 
(Nettelbeck et al., 2000; Nettelbeck, 2008). In one artificial design, bidirectional promoters that 
simultaneously exert control over two key viral genes (i.e., E1A/E1B or E1A/E4) have been 
applied.  Another promoter concept includes a dual-specific hybrid with regulatory elements 
that react to a hypoxic environment and estrogen thereby conferring greater discriminatory 
capabilities to oncolytic CRAdV (Hernandez-Alcoceba et al., 2002). Engineering of these 
transcriptionally-regulated CRAdV is an onerous task and poses several limitations due to the 
variety of viral and non-viral factors which can influence the response of the heterologous 
promoter.   Safety concerns arise when cis-acting enhancer elements or cryptic transcription 
initiation sites lie in the left ITR or packaging signal. These regions that are upstream of E1A 
can influence transcriptional read-through of the E1A or transgene region even in the presence 
of a TRE (Yamamoto et al., 2003). Other elegant designs  which address the limitations include 
the insertion of additional transcriptional terminators or insulators which are upstream of 
heterologous promoters, orientation changes of the E1A expression cassette, or the 
translocation of the packaging signal from the left ITR to the right ITR. 
Post-transcriptional methods which control mRNA stability or translation are also under 
investigation for CRAdV development.  Within the tumor microenvironment, proliferative 
signals are the driving force for expression of specific tumor-associated proteins.  Expression 
of these proteins is boosted partially by the stabilization of mRNA by a 3'UTR which is 
regulated by an activated mitogen-activated protein kinase (P-MAPK ) pathway.  The 3’UTR 
regulates mRNA stability in several genes; hence, ligation of the 3’UTR with crucial AdV 
genes confers the vector with the ability to better target tumors (Sharma et al., 2009b). 
No CRAdV have currently been developed that completely lack the ability to replicate or 
cause some toxicity in normal cells.  They do however confer a great deal of selectivity and 
safety.  Future conceptions should involve the enhancement of tumor-specific replication. 
6.3 Suicide gene therapy 
Suicide gene therapy selectively orchestrates a gene-directed enzyme for prodrug therapy 
(GDEPT) to deliver chemotherapeutic moieties to specific tumors.  Nontoxic drugs (i.e., 
chemotherapeutic agents) are converted by AdV loaded with a GDEPT into cytotoxic agents 
within the tumor. Classic chemotherapy is often harmful to normal cells and, thus, promotes 
deleterious effects with the high doses needed for maintaining therapeutic indices. Since 
nontoxic prodrugs can be administered without harmful side effects to normal cells, this is a 
preferred methodology for chemotherapeutic delivery.    
Two suicide genes which have been well characterized include the herpes simplex virus, type I 
thymidine kinase (HSV-TK) and the Escherichia coli, cytosine deaminase (CD) genes. HSV-TK 
phosphorylates ganciclovir (GCV) which cooperates with DNA polymerase to interfere with 
DNA synthesis ultimately leads to cell death in rapidly dividing cells.  CD transforms 5-
fluorocytosine (5-FC) into a very toxic metabolite 5-fluorouracil (5-FU), which is a frequently 
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used chemotherapeutic (Aghi et al., 1998).  Although direct toxicity is imparted by GDEPT-
mediated cell death, there is also significant growth inhibition/killing of uninfected 
neighboring tumor cells due to the transfer of the toxic drug.  The causes of this event are 
hypothesized to involve transfer via gap junctions or diffusion and stimulation of an anti-
tumor response against lysed tumor cells (Lumniczky & Safrany, 2006).  
Replication-defective AdV were initially used in GDEPT but demonstrated poor anti-tumor 
efficacy. RCAdV have had a better outcome, and the combination of suicide genes with 
standard therapies has further enhanced anti-tumor efficacy. However, GDEPT loaded  
AdV must be administered intratumorally in order to protect normal cells from cytotoxic 
events.   
Other methods have evolved which can be used alone or in combination with the methods 
described above. The transductional targeting of tumors, the selective expression of suicide 
genes, or the addition of tumor specific promoters to AdV essential genes have improved 
anti-tumor potential of AdV vectors.   These suicide gene/prodrug combinations are under 
investigation in both preclinical and clinical trials.  Better dosage regimens and vaccination 
protocols must be formulated in order to improve the therapeutic potential of this system.  
 Another approach to consider for improvement involves thorough documentation of the 
kinetics of the prodrug and vector transgene expression.  Timing prodrug administration in 
order to maximize benefits is of crucial importance.  One novel method that has been 
proposed involves sequential administration of prodrug 5-FC followed by GCV.  This 
double suicide gene therapy produced significant synergistic cytotoxicity.  Avoidance of 
premature cell death is of critical importance since AdV will not be able to replicate.  If virus 
proliferation is inhibited, yield will decrease markedly affecting the benefit of AdV-
mediated suicide gene therapy (Sharma et al., 2009b). 
6.4 Cancer immunotherapy 
An intact immune system is capable of recognizing and eliminating tumor cells in the body; 
however, cancer cells possess the ability to evade immune detection.   Tumor cells have several 
methods to avoid immune detection which include but are not limited to the release of 
immunosuppressive or anti-inflammatory proteins, flawed antigen presentation and 
processing caused by mutations within the mechanisms of antigen presentation or decreased 
expression of MHC molecules. The ineffectual anti-tumor immune response (humoral or cell-
mediated) along with the progression of immunosuppression during oncogenesis 
demonstrates how the immune system needs to be magnified and specificity-modified to 
target tumor cells and the process of oncogenesis.   The objective of cancer immunotherapy is 
to stimulate an endogenous immune response against already established or rapidly 
developing tumors.  AdV have been employed to promote an immune response against 
cancerous cells by transporting immunostimulatory molecules or by arming dendritic cells 
(DC) with the appropriate tumor-associated antigen (TAA) (Sharma et al., 2009b). 
6.4.1 Delivery of cytokines/co-stimulatory molecules via AdV 
The administration of cytokines augments the cytokine environment within the tumor cell 
while also rallying immune cells to elicit an anti-tumor response.  Many cytokines and 
membrane bound receptors (IL-12, IL-2, IFN-gamma, CD40L, etc) are very potent 
immunomodulators but elicit systemic toxicity during exogenous delivery.  They also have a 
short half-life in vivo and are maintained at subtherapeutic levels at the tumor site. AdV 
loaded with cytokine expressing genes which are delivered intratumorally have 
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demonstrated increased patient survival and decreased tumor growth.  IL-2 suppresses 
tumor growth by stimulating cell-mediated killing activities in cytotoxic T lymphocytes 
(CTLs), lymphokine-activated killer (LAK) cells, or tumor infiltrating lymphocytes (TILs) 
(Eberlein & Schoof, 1991). A few clinical trials have exploited the potential of IL-2 in order to 
build an immune response to eventually kill tumor cells.  IL-12 is another cytokine under 
investigation which elicits a potent anti-tumor response when administered locally by 
stimulating proliferation and cytotoxicity of CTLs and natural killer (NK) cells.   A 
replication defective AdV (AdV.TNF) which does not target any particular tumor-associated 
antigen but rather expresses TNF-α under a chemoradiation-inducible promoter is in Phase 
III of clinical trials. The AdV.TNF is administered intratumorally along with radiation and 5-
FU to induce an anti-tumor response.  Co-stimulatory molecules, such as CD40L, have also 
demonstrated an ability to suppress tumor growth and are in Phase I/II of clinical trials 
(Habib-Agahi et al., 2007; Kikuchi & Crystal, 1999; Loskog et al., 2004; Martinet et al., 2000; 
Xu et al., 2005; Yoshida et al., 2003).  
6.4.2 AdV Infection of DCs facilitate cancer immunotherapy 
DCs are efficient and specialized APCs which present MHC-tagged epitopes to T cells in 
order to generate a specific immune response.  These cells have been modified by AdV ex 
vivo so that the DCs either present TAA to effector cells of the immune system and/or 
introduce various immunomodulatory genes (i.e., cytokines or co-stimulatory 
receptors).  Several of the anti-cancer therapies utilizing AdV have coupled the vector with 
the DC’s abilities in order to generate an effective anti-tumor therapy.  This method offers 
several advantages: (1) the AdV demonstrates adjuvant activity and has the ability to 
activate DCs and promote maturation which facilitates the induction of strong anti-tumor 
response (Geutskens et al., 2000; Kanagawa et al., 2008) , (2) AdV expression of TAA within 
DCs permits processing and loading onto both MHCI and MHCII molecules which 
stimulates the appropriate and relatively persistent activation of CD8+/CD4+ responses 
(Xia et al., 2006), and (3) ex vivo treatment of DCs with AdV evades any potential problems 
with pre-existing vector immunity (Wan et al., 1999). 
7. AdV vaccines for infectious diseases 
Significant advancements have been made in recombinant viral-vaccine strategies for 
infectious disease. AdV vaccines have demonstrated remarkable levels of T cell 
immunogenicity. AdV possess the ability to prime the immune response to target a transgene. 
This immune response can be boosted to high levels with a second vector that is recombined 
with the target antigen or with a serotype from a heterologous AdV (Jolly et al., 2008). 
7.1 HIV vaccines  
HIV is a constantly evolving virus that is an imposing challenge in the realm of engineering 
vaccines.  The goal of HIV-1 vaccines is to reduce viral load, prolong survival, and minimize 
transmission. Vaccines that induce the HIV-1-specific cellular immune response have a 
delicate balance to maintain with regard to population preservation and selective 
stimulation. The vaccine construct should preserve the CD4+ T cell population and also 
increase the degree to which the CD8+ and CD4+ T cells recognize and bind HIV-1 antigens 
such as Gag and Pol.  In addition, an elevated titer of neutralizing antibodies which possess 
high-avidity for the native trimeric Env protein of the virus needs to be attained. 
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A HAdV5-based HIV-1 vaccine was tested in humans in a Phase II trial to evaluate the risk 
for acquiring HIV infection. Unfortunately this trial was halted because the monitoring 
board determined that the vaccine was not able to demonstrate protection (Buchbinder et 
al., 2008; McElrath et al., 2008; Priddy et al., 2008). Future goals are focused on additional 
optimization of vaccine immunogens and technologies (Bradac & Dieffenbach, 2009). Since 
other researchers report the ability to induce a high level of cell-mediated immune response 
in non-HIV formulations, this is the time to apply this proof of principle to the area of HIV 
vaccine research.   
In other areas of research, an AdV vector with chimeric fiber is used to infect autologous T 
cells to facilitate HIV therapy.  This chimeric fiber contains both the HAdV5 fiber tail and 
the HAdV35 fiber shaft and knob domains (Perez et al., 2008). Due to its specificity to CCR5, 
CD4+ T-cells treated with this vector are relatively resistant to HIV infection.  The data, 
while preliminary, are encouraging.  Also, the modified CD4+ T cells treated with this 
vector are well-tolerated and engraft, replicate, and persist within the body after a single 
infusion.  They behave like unmodified T-cells in so much as they migrate to the gut mucosa 
where they undergo selective expansion (Barouch, 2010). When used in combination with 
conventional anti-HIV therapies, this strategy might prove beneficial. 
Different immunization strategies include a prime-boost approach with AdV-modified 
vaccinia virus Ankara (MVA) or heterologous HAdV5 and HAdV35 regimens or triple 
combinations which further elicit both T and B cell responses.  The use of HAdV26 and 
HAdV35 in a prime-boost approach has shown promise in avoiding pre-existing vector 
immunity (Barouch, 2010). Immunization with HAdV26-Gag and HAdV35-Gag resulted in 
increased levels of CD127, CD62L, and Bcl-2 on T cells compared to HAdV5-Gag 
inoculation.  These markers are indicative of improved functioning in T lymphocytes.  There 
is also increased proliferation potential as well as increased antigen specificity. 
7.2 Malaria vaccines 
Malaria is characterized by several molecular interactions between the parasite and host 
during the parasite’s incubation.  An effective malaria vaccine will vigorously induce 
protective antibody and T cell responses to various malaria antigens that are expressed 
during the parasite’s differentiation at the various life stages.  Currently a mixture of two 
HAdV-5 vectors which express the pre-erthrocytic-stage malaria antigen circumsporozoite 
protein (CSP) or blood-stage malaria antigen apical membrane antigen 1 (AMA1) have 
demonstrated some success and are in Phase I/II of clinical trials.  After immunization, 
human volunteers had a remarkable response to each antigen.  Depletion studies 
determined that the response was due to a mixed population of CD8+ and CD4+ T 
cells.   The CD8+ T cell lineage was five times greater than the CD4+phenotype when IFN-Ǆ 
secreting cells were assayed within the response population (Draper & Heeney, 2010).   
Another malaria vaccine platform involves the use of rAdV of rarer human serotypes or of 
non-human origin.  These designs are engineered in such a way as to avoid pre-existing 
vector immunity against HAdV5. Some preclinical trials investigate priming with one AdV 
(i.e., HAdV5) and boosting with a heterologous AdV (i.e., HAdV35).  Another strategy uses 
chimpanzee AdV serotype 63 (AdVCh63).   AdVCh63 expresses the pre-erthrocytic-stage 
antigen thrombospondin-related adhesion protein combined with a multi-epitope string 
(ME-TRAP).  A preclinical study utilizing a HAdV5 vector for priming followed with a 
boost by a MVA vector to promote the antibody and T cell responses.  This particular 
HAdV5-MVA protocol used vectors that had been recombined with blood-stage malaria 
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antigen merozoite surface protein 1 (MSP1) which induces a T cell response which was 
partially effective against the liver-stage infection (Draper et al., 2009) and a protective 
antibody response effective against the blood-stage infection (Draper et al., 2008). Future 
studies will have to address the immunogenicity problems of the AdV system that may exist 
when it is used in a target population of African children between the ages of one and 
six.  This age group lives in a highly endemic region for malaria.  It has already been shown 
that vector immunogenicity, provided by sequential immunization with two attenuated 
poxvirus vectors, was less effective in affording protection when immunized children were 
compared with naturally immune adults in Africa and malaria-naïve volunteers from 
developed countries (Bejon et al., 2006).  
7.3 Tuberculosis (TB) vaccines 
AdV vaccine programs are being investigated for human TB, but these programs are slightly 
hindered due to the absence of a good experimental model for humans during 
challenge.   Currently, M. bovis BCG is being developed as a representative challenge for 
human M. tuberculosis (Draper & Heeney, 2010).  The AdV in clinical trials for M. tuberculosis 
aims to circumvent vector immunity by utilizing HAdV35 in place of HAdV5.  AERAS-402 
utilizes a live, replication-deficient rHAdV35 that expresses a fusion protein of three 
Mycobacterium tuberculosis antigens, 85A, 85B, and 10.4 (Radosevic et al., 2007).  This 
platform has demonstrated safety and efficacy in adults that were primed by BCG or 
recombinant BCG. The system intends to increase T cell-mediated immunity and, thus, 
protection from tuberculosis.  Preclinical studies are exploring the potential of aerosolized 
delivery for AERAS-402 in an attempt to intensify mucosal immunity to provide greater 
protection against M. tuberculosis infection.  However, in order to address these issues, more 
preclinical data needs to be collected from non-human primates. 
7.4 Influenza vaccines 
The establishment of an influenza vaccine that protects against multiple strains is a major 
undertaking and a long sought after goal.  Given the current circumstances of the seasonal 
emergence of new permutations of influenza, the past pandemic involving the 2009 H1N1 
influenza type A strain, and the possibility of highly pathogenic avian influenza to attain 
pandemic potential, accomplishing this goal is imperative. Inducing variant-specific 
antibody responses against the surface antigens, hemagglutinin and neuraminidase, is not 
the best way to combat influenza viruses which are constantly changing their surface 
proteins due to antigenic drift. Initiating a strong T cell response in addition to neutralizing 
antibody response to conserved T and B cell epitopes is important for protection against 
influenza variants.    
AdV-based influenza vaccines provide particular advantages over egg-based influenza 
vaccines due to their low production costs and the quick and easy manufacturing of a 
substantial amount in validated cell lines. Replication-competent as well as replication-
defective AdV vectors have been developed to express distinct influenza antigens.  Each 
construct has been evaluated for its immunogenicity and efficacy in a variety of animal 
models, and a few formulations have been evaluated for the safety and efficacy in clinical 
trials in humans.   
Immunization of mice with an AdV expressing the HA gene from swine influenza virus -
A/Swine/Iowa/1999 (H3N2) resulted in high levels of influenza-specific neutralizing 
antibodies.  Also, the immunization led to partial protection against a lethal challenge with a 
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heterologous virus [A/HK/1/1968 (H3N2)] (Tang et al., 2002). Intranasal or epicutaneous 
immunization of humans with a replication-defective AdV encoding the HA gene of 
A/PR/8/1934 (H1N1) influenza virus resulted in a fourfold increase in hemagglutination 
inhibition (HI) titers in 83% of the participants (Van Kampen et al., 2005).  The presence of 
pre-existing vector immunity did not seem to have a significant impact on the resultant 
hemagglutinin (HA)-specific immune response.   
A replication defective HAdV5 influenza A (HAd-H5HA) vaccine containing the HA gene 
from HK/156/97 (H5N1) was evaluated for immunogenicity and protection in a mouse 
model (Hoelscher et al., 2006). The immunization resulted in the development of epitope-
specific CD8 T cells and virus neutralizing antibodies.  HAd-H5HA expresses HA from 
H5N1 influenza strain A/Hong Kong/156/1997 (HK/156/97) and is administered 
intramuscularly or intranasally.   This vaccine construct provided complete protection to 
mice when challenged with homologous (HK/156/97) or heterologous (VN/1203/04) 
H5N1 influenza virus challenge indicating that HAd-H5HA afforded cross-protection to 
antigenically distinct strains of highly pathogenic H5N1. Immunized mice with HAd-
H5HA were fully protected following challenge with a homologous H5N1 virus even 
after one year following immunization (Hoelscher et al., 2007). Inclusion of the HA genes 
from clade 1 and clade 2 H5N1 influenza viruses and the NP gene from one of the clades 
in the AdV-based vaccine resulted in expanded protection (Hoelscher et al., 2008). A 
replication-defective AdV vector expressing the HA gene from a H5N1 influenza virus 
has been tested in a Phase 1 clinical trial.  The replication competent HAdV4 vector-based 
vaccine containing the HA gene of a H5N1 virus induced both humoral and mucosal 
antibodies as well as a cellular immune response when administered in a enteric capsule 
(Palkonyay, 2009).  
An AdV vector provokes both humoral and cellular immune responses. If an AdV is 
engineered to carry multiple genes from different influenza strains, this will enhance the 
cross-protective efficacy against multiple strains. An AdV that is loaded with cross-reactive 
potential will provide a stockpiling option to address the vaccine need for a potential H5N1-
based pandemic influenza (Vemula & Mittal, 2010). 
7.5 Filovirus vaccine 
In the effort to battle Ebola and Marburg viruses, a Phase I study has been completed using 
a mixture of two replication-deficient, rAdV5 (Ebola-rAdV5) encoding glycoproteins (GP) 
from Zaire and Sudan-Gulu strains, as well as the nucleoprotein (NP) of filovirus. It 
demonstrated excellent pre-clinical results with 100% protection in monkeys, but, 
apparently, it did not do well in human clinical trials (Martin et al., 2006). Virus neutralizing 
antibodies that were specific for the virus strains used in the trial were undetectable in the 
persons vaccinated.  It was also determined that NP was not necessary for inclusion in the 
vaccine construct and may actually dampen the protective immune response (Sullivan et al., 
2006).  
8. Improving adenovirus based gene transfer- strategies for immune evasion 
Staggering innate and adaptive immune responses have undoubtedly limited the 
therapeutic potential of AdV based gene transfer. However, the extensive promise that Ad 
vectors offer for improving human and animal health has fueled tremendous interest in 
acquiring a deeper understanding of molecular mechanisms underlying the immune 
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activation. Several promising innovative strategies to eliminate or minimize the acute 
inflammatory responses induced by AdV vectors, as well as to circumvent the vector 
immunity in order to prolong the vector persistence in host are being developed. 
8.1 Immunosuppression and immunomodulation  
Elimination of a significant fraction of intravascularly administered AdV vectors within 
initial twenty-four hours is attributed to elements of non-specific innate immune response, 
particularly the liver Kupffer cells, acting as a buffer against invading pathogen. Hepatocyte 
transduction occurs only after the saturation of kupffer cells at higher doses (Di Paolo et al., 
2009). Removal of Kupffer cells is expected to result in higher hepatocyte transduction 
efficiency. In fact, transient depletion of macrophages prior to vector inoculation using pre-
treatment with gadolinium chloride (GdCl3) or dicholoromethylene bisphosphate (Cl2MBP) 
not only reduces the initial vector clearance, but also seem to prolong the long-term 
transgene expression, possibly through attenuating the vector-specific adaptive immune 
responses (Kuzmin et al., 1997; Lieber et al., 1997). Although an effective macrophage 
depletion strategy may not be able to prevent vector elimination entirely since other 
mechanisms are also involved, this strategy might be used effectively in combination with 
other immune suppression methods.    
The anti-vector humoral and cytotoxic immune responses are primarily responsible for 
preventing long-term transgene expression and act by eliminating the vector-transduced 
cells. Several studies have shown that treatment with non-specific immunosuppressive 
agents such as cyclosporine A, cyclophosphamide, deoxypergualin, dexamethasone and 
FK506 at the time of vector administration in presence of pre-existing immunity can 
suppress progression of humoral and/or cellular immune response and prolong the 
persistence of transgene in the host (Kaplan & Smith, 1997; Kuriyama et al., 2000; Seregin et 
al., 2009; Smith et al., 1996; Thomas et al., 2008). Similar effects can be obtained through 
transient immunosuppression by using specific antibodies targeted against molecules such 
as T lymphocyte antigens, CD4, CD40, or CD86 to block the receptor-ligand interaction 
(Chirmule et al., 2000; Haegel-Kronenberger et al., 2004; Ye et al., 2000). Many AdV vector 
applications require administration of high vector doses and, therefore, necessitate 
prevention or mitigation of an AdV-induced acute inflammatory response. Simultaneous 
administration of suppressor of cytokine signaling 1 (SOCS-1) results in generalized lower 
serum levels of cytokines, including IL-6, MCP-1, RANTES and TNF-ǂ (Sakurai et al., 2008). 
Other studies have targeted suppression of specific cytokines, for example, TNF-ǂ 
(Wilderman et al., 2006) and IFN-ǂ/ǃ (Zhu et al., 2007) resulted in significant reduction of 
the inflammatory response. Interestingly, a regimen for the inhibition of multiple cytokines 
at same time may have an additive or synergistic effect on inhibition of the inflammatory 
response. However, caution must be exercised for interpreting the results of such studies as 
species-specific variations may exist, and the observation made in animal models may not 
be replicated in humans. Each immunosuppressive or immunomodulatory approach needs 
to be thoroughly evaluated for potential side effects before their transition to clinical trials. 
Additionally, although transient, a generalized immunosuppression might render the 
patients more vulnerable to other diseases.  
8.2 Vector modifications  
Strategies involving vector modifications impose lesser risk to the host than those that 
involve attenuating or modifying host immune responses. Vector modifications can be 
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achieved through several different strategies, each with its own advantages and 
disadvantages, and will vary pertinent to the specific application. Vector modifications can 
consist of many alternatives such as (1) those intended to ablate interactions between AdV 
and its primary and/or secondary receptor, (2) fiber knob modifications to retarget vector to 
specific cell types, (3) replacement of fibers using serotype chimerism, (3) covalent 
modifications, (4) vector pseudotyping, and (5) vector microencapsulation. 
8.2.1 Fiber knob modification  
Binding of the HAdV5 fiber knob domain to CAR on the cell surface is the foremost step in 
virus entry. Multiple strategies are available for altering the natural biodistribution pattern 
of AdV vectors and retargeting them to specific cell types. Complexing the vector with a bi-
specific antibody for recognizing the fiber knob or a specific cell surface molecule will serve 
the dual purpose of ablating knob-CAR interaction and targeting the modified vector to an 
alternative receptor (Curiel, 1999; Mizuguchi & Hayakawa, 2004). Alternatively, the vector 
can be treated with a CAR ectodomain-single chain antibody targeted against a tissue-
specific antigen. The CAR ectodomain will bind to the fiber knob preventing interaction 
between CAR on cell surface. The single chain antibody will retarget the vector to the 
specific cell type (Li et al., 2009). In vivo, the fiber knob domain also interacts with 
coagulation factor IX and factor C4BP, targeting AdV vectors to HSPGs and LRP on 
hepatocytes and Kupffer cells. Consequently, fiber knob modifications might also ablate 
these interactions, thereby reducing liver transduction and subsequent hepatotoxicity 
(Shayakhmetov et al., 2005). 
8.2.2 Serotype chimerism 
Chimeric AdV vectors are most commonly constructed by replacing the knob domain or 
whole fiber with one from an alternative AdV serotype. Remarkable similarities among 
fibers of different Ad serotypes allows for the ‘fiber chimerism’. Since the subgroup B 
viruses use cell surface molecules other then CAR as their primary attachment receptor, it 
is credible to replace HAdV5 fiber knob with one of a subgroup B virus, or vice versa, and 
expect a shift in vector biodistribution. Expectedly, fibers from subgroup B AdV have 
been successfully used for constructing HAdV5-based fiber chimeric vectors with an 
altered biodistribution pattern compared to HAdV5 alone. For example, HAdV5 carrying 
a fiber knob from HAdV16p, a subgroup B virus, showed greater transduction of 
cardiovascular and synovial tissues (Havenga et al., 2001). Similarly, HAdV5 with fiber 
from HAdV35, another subgroup B virus, showed enhanced transduction of 
hematopoeitic cells and human pancreatic cancer cells in vitro (Shayakhmetov et al., 2000; 
Toyoda et al., 2008).  
Alternatively, the replacement of only the knob domain instead of the whole fiber has also 
been evaluated. A HAdV5 vector with fiber knob domain from HAdV3 proved to be 
remarkably efficient for gene transfer in animal models of breast cancer, ovarian cancer, 
gastric cancer and renal cancer and also showed good oncolytic ability (Ranki & Hemminki, 
2010). A recent study explained the possibility of exploiting non-human AdV vectors for 
constructing fiber chimerism. Replacing the HAdV5 shaft and knob domains of HAdV5 
with those from a bovine AdV ablated the vector interaction with blood factors IX and X and 
the subsequent HSPG-mediated hepatocyte transduction. As a result, serum levels of many 
of the pro-inflammatory cytokines and chemokines at early time points after the 
intravascular inoculation were significantly reduced (Rogee et al., 2010). 
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The major capsid protein hexon of HAdV5 interacts with factor X and mediates hepatocyte 
transduction. Being the most abundant capsid protein, it is expected to contribute 
significantly to non-CAR-dependent tropism. However, not all AdV serotypes bind factor X, 
and therefore, have variable hepatocyte transduction profiles in vivo. Chimeric HAdV5 27 
vectors whose HVRs were replaced with HVRs of HAdV26 or HAdV27, which do not bind 
factor X, ablated factor X binding and showed a reduced hepatocyte transduction at a 
comparatively high dose (1011 vp/mouse). However, a greater degree of macrophage 
transduction was observed, giving a possible reason for the concomitant higher degree of 
proinflammatory cytokine and chemokine response following intravascular administration 
of the hexon chimeric HAdV5 vector. Interestingly, inserting HAdV35 fiber in place of 
native fiber of this chimeric HAdV5 vector dramatically increased lung transduction by 
more than 16000 times compared to the vector with HAdV5 fiber (Alba et al., 2010). Such a 
vector may prove very useful for lung gene therapy applications. Furthermore, this study 
also highlighted an interesting possibility of combining hexon and fiber chimerism to 
construct novel vectors with decreased immunogenicity and suitability for a particular 
application. Recently, another study reported a chimeric HAdV5 vector with the hexon from 
HAdV3. This chimeric vector showed ablation for factor X binding, which translated into 
reduced liver transduction and enhanced anti-tumor activity, owing to greater 
bioavailability of the vector for tumor transduction (Short et al., 2010). 
8.3 Covalent modification of Ad capsid  
Covalent modification of AdV capsids is an attractive alternative to genetic modification for 
preventing induction of immune responses and the acute toxicity following systemic 
administration. Addition of chemical groups to AdV capsids masks the natural 
immunodominant epitopes and the molecular patterns required for interaction with Ad-
neutralizing antibodies along with the pattern recognition receptors, thereby preventing 
antibody-mediated vector clearance and induction of innate immune responses. Several 
standardized methods for covalent modifications are available for the generation of high 
titer stocks of modified vectors. Furthermore, simultaneous modification of a large number 
of capsid amino acids is feasible with covalent modification which may not be possible 
through genetic modification. Multiple studies have reported the so-called ‘stealth AdV 
vectors’ modified with synthetic polymers, for example, polyethylene glycol (PEG) (Kreppel 
& Kochanek, 2008). In accordance with the above principles, covalently modified AdV 
vectors have been shown to prevent or attenuate the induction of innate and adaptive 
immune responses, as well as, to evade pre-existing AdV-neutralizing antibodies (Croyle et 
al., 2002; Croyle et al., 2005). In addition, the use of bifunctional PEG allows for tissue-
specific targeting of AdV vectors by coupling one functional group to capsid proteins and 
another functional group to a ligand of a specific tissue receptor (Park et al., 2008).  
8.4 Alternative Ad vectors  
Since AdV-neutralizing antibodies are serotype-specific and the prevalence of some of the 
HAdV serotypes in the human population is rare, HAdV vectors derived from the rare 
HAdV serotypes can potentially circumvent the pre-existing vector immunity, and, 
therefore, be more effective than vectors derived from common HAdV serotypes such as 
HAdV5. Vector systems based on HAdV serotypes in all subgroups have been reported 
(Appledorn et al., 2008a). 
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8.5 Non-human Ad vectors  
Vectors based on nonhuman AdV serotypes are very promising candidates to serve as gene 
delivery vehicles and are frequently derived from AdV infecting bovine, porcine, ovine and 
chimpanzee. The nonhuman AdV do not cause disease in humans and are not neutralized 
by the HAdV-specific neutralizing antibodies (Moffatt et al., 2000; Sharma et al., 2010; Singh 
et al., 2008). In addition, nonhuman AdV vectors have been shown to transduce human cells 
in culture and express transgene (Bangari et al., 2005; Bangari & Mittal, 2004; Farina et al., 
2001; Klonjkowski et al., 1997; Mittal et al., 1995; Rasmussen et al., 1999). Advances in the 
past decade signify the potential of nonhuman AdV vectors as effective gene delivery 
vehicles without any significant toxicity and interference from pre-existing immunity. A 
bovine AdV serotype 3 (BAdV3) vector has been shown to possess low liver tropism, 
prolonged vector genome persistence and, thereby, higher transgene expression than a 
HAdV5 vector in the heart, lungs, and kidneys of mice following intravenous inoculation 
(Sharma et al., 2009a). The humoral as well as cellular immune responses generated against 
various non-human AdV are expected to be non cross-neutralizing (Sharma et al., 2010). 
Sequential use of alternative non-human AdV-derived vectors  might prolong the transgene 
expression and, therefore, the desired therapeutic effect. 
9. Conclusion 
The future of AdV vectors is very promising.  Much research has been conducted on the 
various constructs of the vectors with the hope of finding therapies that will enable specific 
targeting of diseased cells or tumors thereby causing minimum harm to surrounding cells or 
organs.  With continued research on the mechanisms of AdV gene expression and tissue 
tropism, the medical and scientific communities have great reason to anticipate 
breakthroughs in cancer and vaccine therapies.  
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